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ABSTRACT 
 
The epidermal growth factor receptor (EGFR) can be internalized through different routes. 
While clathrin-mediated endocytosis destines EGFR for recycling and signaling, 
internalization through non-clathrin endocytosis (NCE) targets the receptor for degradation. 
Since NCE appears to be a major negative regulator of EGFR levels, a more complete picture 
of this pathway would likely reveal new insights into aberrant EGFR signaling observed in 
many types of cancer.  
By combining a candidate gene approach with an unbiased proteomic approach, we 
have defined EGFR-NCE as molecularly distinct from other NCE pathways, relying on 
functional regulators not previously implicated in endocytosis. We found that reticulon 3 
(RTN3), an endoplasmic reticulum (ER)-resident protein, is fundamental for NCE-mediated 
EGFR internalization, and that its ablation delays EGFR degradation, demonstrating that the 
NCE pathway is a critical regulator of the EGF-dependent cellular response. We show that, 
upon stimulation with high dose of EGF, RTN3 is localized in close proximity to EGFR and 
that it is crucial for the formation of contact sites between the ER and the plasma membrane 
(PM), which are needed for NCE to proceed efficiently. We also show that ER contact sites 
are involved in local Ca
2+
 release: high EGF doses induce a release of Ca
2+
 from the ER to the 
PM, which is strongly inhibited upon knockdown of RTN3. This calcium release depends on 
the inositol trisphosphate (IP3) cascade and is essential for the internalization of EGFR via 
NCE.  
In conclusion, we have discovered a new clathrin-independent endocytic pathway that 
relies on the action of RTN3. RTN3 is necessary for the formation of contact sites between 
the ER and EGFR-NCE sites at the PM, which are required for IP3R-dependent local calcium 
release and the completion of EGFR internalization through NCE. 
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INTRODUCTION 
 
1. Endocytosis: cells orchestrate multiple entry routes  
The plasma membrane (PM) defines the space of a single cell and is a dynamic structure, 
essential in capturing and decoding signals coming from the extracellular space. Endocytosis 
is a fundamental process that allows the cell to communicate with the extracellular 
environment and to regulate membrane composition. In the cell, various types of endocytic 
routes coexist and operate in parallel to precisely regulate PM composition and signaling. 
Diverse types of endocytosis are classified based on the size of endocytic structures: 
phagocytosis and macropinocytosis are responsible for great rearrangements of the PM 
caused by the uptake of large particles and the extracellular milieu, respectively. 
Micropinocytosis, instead, is characterized by small membrane invaginations involved in 
different types of internalization processes, including the well-characterized clathrin-mediated 
endocytosis (CME) and a vast number of non-clathrin endocytic (NCE) processes (Figure 1 
and Table 1). 
Adapted from Mayor, Cold Spring Harb Perspect Biol, 2014 (1) 
Figure 1. Endocytic pathways.  
Endocytic pathways are represented: on the left, micropinocytic pathways, characterized by 
dynamin (pink circles) dependence (+) or independence (-); on the right, macropinocytosis 
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and fagocytosis that are dynamin independent. All dynamin-independent pathways appear to 
require the actin machinery (red bars).  
 
Pathway 
Morphology 
and size 
 
Coat 
Dynamin 
dependence 
Small 
GTPase 
involved 
Internalized 
 cargoes 
Associated/ 
regulatory proteins 
 
 
Phagocytosis 
 
 
Cargo shaped 
> 500 nm 
 
 
None 
 
 
No 
 
Rac1, 
RhoA, 
Cdc42 
 
Pathogens, 
apoptotic cells, 
FcRs 
Actin, ARP2/3, 
formins, PI3K, 
WASP, WAVE2, 
amphiphysin, 
coronin, others 
 
Macro- 
pinocytosis 
 
Ruffled 
0.2-10 μm 
 
None 
 
In some 
cases 
 
Rac1, 
Cdc42, 
Arf6, 
Rab5 
 
RTKs, fluids, 
some bacteria 
Actin, ARP2/3, 
cortactin, PI3K, 
SRC, PAK1, RAS, 
CTBP1/BARS, 
others 
 
Clathrin- 
mediated 
 
Vesicular 
100-200 nm 
 
 
Clathrin 
 
 
Yes 
 
 
Rab5 
RTKs, GPCR, 
TfR, some 
toxins, 
bacteria, 
viruses 
AP-2, 
EPSINS,EPS15,inter
sectin, amphiphysin 
(plus many others, 
>50) 
Caveolae-
mediated 
Flask-shaped 
50-120 nm 
Caveolin 1 
and 2 
 
Yes 
 
Not clear 
GPI-linked 
proteins, 
CTxB, SV40 
PTRF/cavin, SRC, 
SDPR, SRBC 
 
 
CLIC/GEEC 
 
 
Tubular 
 
 
No 
 
 
No 
 
Cdc42, 
Arf1 
Fluids, bulk 
membrane, 
GPI-linked 
proteins 
 
Actin, GRAF1, 
ARHGAP10 
 
IL2Rβ 
Vesicular 
50-100 nm 
 
Yes 
 
Yes 
 
RhoA, 
Rac1 
IL2Rβ, γc-
cytokine 
receptor 
PAK1 and 2, 
cortactin, N-WASP 
 
Arf6- 
dependent 
 
Tubular 
 
None as 
yet 
 
None as yet 
 
Arf6 
MHCI, 
MHCII, 
CD59, CD55, 
GLUT1 
 
None as yet 
Flotillin- 
dependent 
Vesicular No No None CTxB, CD59, 
proteoglycans 
None as yet 
 
FEME 
 
Tubular 
 
No 
 
 
Yes 
 
RhoA, 
Rac1 
IL2-R, iota 
toxin, CTxB, 
STxB 
PAK1, PAK2, 
Endophilin-A’s 
 
Table 1. Internalization pathways.  
The table summarizes internalization pathways described in the literature. Morphology and 
size of the internalizing structures, the presence or not of a coating protein, the dependence on 
dynamin, the kind of GTPases involved, the type of internalized cargo, and known associated 
proteins are listed for each internalization pathway.  
CLIC, clathrin-independent carriers; GEEC, GPI-AP enriched early endosomal compartment; 
RTK, receptor tyrosine kinase; GPCR, G protein-coupled receptor; TfR, transferrin receptor; 
CTxB, cholera toxin B; SV40, simian virus 40; GPI, glycosylphosphatidylinositol; MHC, 
major histocompatibility complex; PTRF, polymerase I and transcript release factor; SDPR, 
serum deprivation response; SRBC, SDR-related gene product that binds to c-kinase; CtBP1, 
C-terminal binding protein 1. 
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1.1 Phagocytosis 
Phagocytosis is defined as the process used by specific cells to engulf particles, cellular debris 
and microorganisms with diameters greater than 500 nm (2). The first step of this process is 
the recognition of the particle by specific receptors; the phagocytic cup is then formed thanks 
to the polymerization of F-actin. The actin reorganization process is strictly regulated by 
different GTPases, among which Rac1, whose activation, according to recent evidence, can be 
regulated directly by mechanical signaling coming from changes in membrane tension (3). 
The internalization of engulfed particles then proceeds through the formation of the 
phagosome and, through acidification, leads to the degradation of the content (for a recent 
review see (4)).  
 
1.2 Macropinocytosis 
Macropinocytosis is an actin-based endocytic process used by cells to engulf extracellular 
fluid (5). The initial step is membrane ruffling, which is driven by actin polymerization; Rac1 
is the main GTPase involved in this process and the system is regulated by Pak1 (p21-
activated-kinase) (6). Recent data suggests that the deactivation of Rac1 is fundamental for 
the completion of macropinosome formation, while the dependence on dynamin for the 
scission is not yet clarified, although it may be required in some types of macropinocytosis 
(7). 
Growth factors are known to be able to stimulate macropinocytosis (8). More in detail, 
a macropynoctic-like pathway has been shown to be involved in the internalization of a vast 
percentage of activated EGFRs (epidermal growth factor receptor). This pathway is 
characterized by the involvement of circular dorsal ruffles/waves that, for their action, require, 
among others, actin, cortactin, dynamin 2 and EGFR kinases. How the entrance into this route 
is regulated is not defined. Indeed, one of the possibilities is that, considering that the 
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activation mode of this pathway leads to the internalization of a large portion of the PM, 
EGFR can be internalized because of this massive rearrangement (9). 
 
 1.3 Clathrin-mediated endocytosis 
Since their first purification in 1975, clathrin-coated vesicles have been extensively studied. 
Clathrin-coated vesicles contain the internalized cargo, surrounded by different clathrin-
adaptor proteins. Adaptor proteins are required for the formation of the outer clathrin layer 
and have a regulatory function in the formation of the pit.  
 
1.3.1 Clathrin-coated pits 
Clathrin can assemble into a lattice of hexagons and pentagons (Figure 2a), while in the non-
assembled form it exists as a three-legged structure called triskelion. Each triskelion is made 
of three copies of a 180 kDa protein, the clathrin heavy chain (CHC), that form the structural 
basis of the lattice; and three copies of the clathrin light chain (CLC, 25 kDa) that regulate the 
formation of the lattice. During recent years, imaging techniques have drastically evolved, 
leading to an extremely high resolution of clathrin-coated pits. Thanks to cryo-electron 
microscopy (cryo-EM), all connections between each single triskelion can be visualized 
(Figure 2b). The domains of the CHC have been identified and their specific function and 
structure has been characterized. The terminal domain of clathrin heavy chain has binding 
sites for adaptor proteins and is connected through a linker, an ankle and a distal segment to 
the proximal segment. The latter is the binding site for the CLC (Figure 2c, (10-13)). 
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Adapted from Robinson, Traffic, 2015 (10) 
Figure 2. Clathrin structure.  
a) Electron micrograph of clathrin-coated pits budding from the plasma membrane.  
b) Hexagonal barrel showing the positions of the clathrin heavy chain (left, red and yellow); 
and of the light chains (right, yellow).  
c) Clathrin triskelion, showing the various domains as reported. 
 
Purified clathrin can per se, as well as in the presence of adaptor proteins, assemble in 
vitro. In the cell, the formation of the clathrin-coated vesicles is a tightly regulated process. 
Concomitantly with the initial membrane invagination, started by the concerted action of 
clathrin and adaptor proteins, the recognition of the cargo is necessary, empty vesicles are 
aborted otherwise. After stabilization, clathrin polymerization facilitates the formation of a 
‘neck’ where membranes are in close apposition. At this level, the GTPase dynamin plays a 
fundamental role, acting at the pinching-off step (Figure 3).  
 
 
b
B 
 a 
c
C 
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Adapted from Traub, Nat Rev Mol Cell Biol, 2009 (14) 
Figure 3. Clathrin coat assembly.  
The figure describes the different steps of clathrin-coated vesicle formation. The formation of 
a clathrin-coated pit start from nucleation of AP2 and adaptor proteins at the PM. During the 
growing phase, the clathrin coat protein is recruited by AP2 and other accessory proteins that 
facilitate the formation of a polymerized coat. The structure is stabilized by actin filaments 
and finally detached from the PM by the action of dynamin. 
 
1.3.2 Adaptor proteins 
Since the first purification of clathrin-coated vesicles, the presence of other proteins, linked to 
clathrin, was evident. These proteins have been purified through the years. The first two 
isolated proteins were adaptor protein-1 (AP1), involved in the transport between trans Golgi 
network and endosomes, and adaptor protein-2 (AP2), involved in endocytosis; followed by 
many others. AP2 is the principal component of CCPs and is the best characterized adaptor 
proteins. AP2 has two large subunits of 100 kDa, named α and β; a medium subunit of 50 
kDa, μ; and a small subunit of 20 kDa, σ. The two large subunits, α and β, possess a globular 
C-terminal region that is linked to the N-terminal ‘head’. The α subunit, also called ‘ear’, 
interacts with phosphoinositides at the level of the PM and with proteins containing the DPF 
and DPW motifs (Figure 4). The interaction with clathrin occurs through the β domain, while 
the μ and σ domains are involved in cargo recognition. Many studies also led to the 
identification of the consensus YXXϕ (where ϕ represents any bulky hydrophobic residue) 
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that, together with the dileucine motif (possessed by EGFR and TfR), is characteristic of 
CME. 
 
Adapted from Robinson, Traffic, 2015 (10) 
Figure 4. The AP complex.  
Schematic diagram of an AP complex, showing the four subunits β, μ σ and γ or α, and the 
clathrin box. 
 
 
All stages of clathrin pit formation have been dissected (15) and many other clathrin-
associated proteins have been identified, many of which are associated to coated pits at a 
specific stage of pit formation or vesicle maturation. An example of this specific recruitment 
is auxilin, which arrives immediately after vesicle scission and recruits Hsc70 to direct 
uncoating of the pit (15-17). Another example is Hip1R, which binds to the clathrin light 
chains and is involved in actin recruitment, a process that in some cases is needed for the 
maturation and budding of coated vesicles (18-20). 
Other accessory proteins with a specific cargo-recognition motif are epsins and Eps15 
(epidermal growth factor receptor substrate 15), which recognize ubiquitinated cargos. Epsins 
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are able to bind clathrin and associate with Eps15 thanks to the binding of epsin NPF motifs 
with the Eps15 homology (EH) domain of Eps15 (21). Moreover, both epsins and Eps15 have 
a DPF/DPW motif and bind AP2 (21). Epsins and Eps15 are redundantly necessary for CME 
of EGFR (22). Moreover, the function of epsin and Eps15 is not unique for CME, indeed, our 
laboratory has showed that they are also involved in EGFR-NCE (22).  
 
 1.4 Non-clathrin endocytosis (NCE)  
CME is a well-characterized pathway. Historically, CME has been considered the major 
endocytic route and was recently described as the principal pathway contributing to the 
endocytic flux in basal conditions in some cellular context (23). However, parallel to CME, a 
number of non-clathrin endocytic pathways have evolved and are all un-affected by clathrin 
ablation but are dependent on raft domains (1,24). These rafts are cholesterol-enriched 
assemblies of lipids and proteins that can interact with each other to form larger and more 
stable domains (25). NCE pathways can be constitutive or triggered by a specific signal and 
are, more in general, categorized based on their dependence on (1):  
i) dynamin 
ii) coat proteins: like caveolins or flotillins 
iii) small GTPases: like Arf6, RhoA, Cdc42 
The classification of different NCE pathways is not always linked to stringent criteria, 
but some features lead to the identification of major endocytic routes. 
 
1.4.1 Caveolae-mediated endocytosis  
Caveolae are small membrane invaginations with a diameter of 60-80 nm, and their presence 
in cells depends on the tissue; for example, caveolae are almost undetectable in kidney cells, 
but represent 50% of the PM in adipocytes (26). There are three types of caveolin (Cav) in 
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mammalian cells: Cav1, Cav2 and Cav3, the first two are usually co-expressed in different 
cell types, while Cav3 is mainly expressed in striated muscle cells. Cav1 is fundamental for 
the formation of caveolae: loss of Cav1 causes the disappearance of caveolae and the 
exogenous expression of Cav1 is sufficient to trigger caveolae formation in cells lacking 
endogenous caveolins (27). 
All caveolins are integral membrane proteins characterized by both N- and C-termini 
that face the cytoplasm, and a putative hairpin domain embedded into the PM (Figure 5). 
Cav1 is the more studied caveolin, it is palmitoylated, oligomeric and is able to bind 
cholesterol and fatty acids (28,29). 
 
Adapted from Parton and Simons, Nature reviews, 2007 
Figure 5. Caveolin topology.  
Membrane topology of caveolin, the N- and C-termini face the cytoplasm and the hairpin 
domain is embedded into the PM.  
 
 
The formation of caveolae is strictly regulated by cavins, which are cytoplasmic 
proteins recruited to caveolae that are needed for the stabilization of caveolin oligomers. 
Among the cavin proteins: cavin1 (also known as PTRF) and cavin-2 and -3 have been 
described as substrates for protein kinase C (PKC) (reviewed in (30)). Once formed, the 
budding of caveolae from the PM requires dynamin. 
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The formation of higher-order structures named rosettes or caveolar clusters is 
characteristic of caveolae (Figure 6a). These structures are peculiar for specific tissues like 
white adipose tissue and endothelia. In the first case, caveolae ere involved in lipid regulation, 
while in the second case, caveolae are used as membrane reservoirs in response to mechanical 
stress of the cell (31,32). In particular, considering the great membrane-capacity of rosettes, 
disassembly of these structures can buffer membrane tension in response to mechanical stress 
(31). Through exocytosis, the same type of protection can occur to provide physical 
protection against lysis. Opposite to exocytosis, endocytosis of caveolar clusters has been 
associated with wound repair (33). For the regulation of all these functions, the interaction of 
caveolae with actin, in particular with stress fibers, is fundamental (32). Stress fibers are in 
turn fundamental for focal adhesions. Several studies suggest a role for Cav1 also in the 
regulation of focal adhesions, especially through endocytosis of integrins, indicating an 
association between caveolae and the extracellular matrix (ECM) (Figure 6b).  
The emerging picture for caveolae is dynamic; their role in endocytosis is still debated 
but it is known that their dynamics are differently regulated depending on cell type and along 
the cell cycle. During mitosis, there is an increased localization of Cav1 into vesicles, 
possibly important for the equal redistribution of Cav1 into the two daughter cells (34).  
 
 
 
 
 
 
Adapted from Echarri and Del Pozo, Journal of Cell Science, 2015 (32) 
Figure 6. Association of caveolae with stress fibers.  
a) Electron microscopy image of a caveolar rosette. Ruthenium Red labeling (dark signal) 
shows the connection of the rosette with the outside of the cell (*).  
b) Electron microscopy showing caveolae co-aligned with stress fibers (black). 
a b
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1.4.2 Flotillin-mediated endocytosis 
Flotillin-1 and -2 (reggie-2 and reggie-1, respectively) acquired their names because they 
were found associated with the so-called floating fraction of lipid rafts after solubilization of 
membranes in Triton X-100 (35). These membrane-associated proteins are expressed in 
mammals, bacteria, plants, fungi and metazonas but not in budding yeast and C. elegans, and 
have a conserved sequence (36).  
Flotillins are ubiquitously expressed in different cellular types and have a dynamic 
subcellular distribution. Originally, flotillins were defined as proteins associated with 
caveolae, but later studies changed this idea: depending on the cell context, flotillins can be 
found at the PM, the Golgi complex, endosomes, lysosomes and exosomes. In particular, 
flotillins can be found associated with endosomes when cells are stimulated with EGF, but no 
co-localization has been found prior to 15 minutes of cell stimulation. The ablation of 
flotillins does not have any effect on EGF internalization (37), thus suggesting that they are 
more likely a cargo in this internalization process rather than effectors/regulators. Moreover, 
flotillins-1 has not been found to co-localize with transferrin, while its ablation is reported to 
impair the internalization by fluid phase of the GPI-linked protein CD59 (38), even if this 
point is under debate (39).  
Flotillins are thought to work in the localization of some cargoes at the PM, indeed, 
together with the prion protein (Prp), they are involved in the recruitment of the transporter 
Glut4, cadherin, and TCR to the PM in adipocytes, in embryonic and epithelial cells, and in 
lymphocytes, respectively (40).  
 
1.4.3 CLIC-GEEC pathway  
It has been reported that the major fluid phase endocytic pathway, at least in fibroblasts, is the 
so-called clathrin-independent carrier (CLIC)-GPI-anchored protein-enriched early 
endosomal compartments (GEEC) (41). Through this pathway, large amounts of extracellular 
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fluids, glycosylphosphatidylinositol (GPI)-anchored proteins, CD44, major histocompatibility 
complex class I (MHCI), and toxins like Shiga and cholera are internalized (42,43). 
The morphology of CLIC-GEEC is tubulo-vesicular and the size of the structures is 
40-80 nm. Membranes associated with this pathway are highly dynamic and connected with 
the activity of the small G-proteins Cdc42 and the BAR protein GRAF1 (GTPase regulator 
associated with focal adhesion Kinase-1), which exhibit a GAP activity for Cdc42. The 
GTPase activity of Cdc42 is necessary for the recruitment of the actin machinery required for 
the execution of the endocytic process. The BAR domain of GRAF1 is needed for membrane 
curvature and, together with the pleckstrin homology (PH) -domain, localizes GRAF1 to 
(phosphatidylinositol 4,5-bisphosphate) PI(4,5)P2 -enriched lipid structures. In addition, 
GRAF1 possess an SH3 domain through which it interacts with dynamin that, however, is not 
needed for the internalization step but is recruited later in the endocytic process.  
Depletion of GRAF1 causes a 60% reduction in the internalization of dextran, a 
typical cargo for this pathway, but has no effect on transferrin internalization, which occurs 
only through CME. Recently, the same selective block of the pathway, following the CLIC 
cargo CD44, has been observed in cells treated with the inhibitor of glycosylceramide 
synthase (DL-threo-1-Phenyl-2-palmitoylamino-3-morpholino-1-propanol, PPMP). This 
effect has been related to the requirement of a fraction of CLICs on galectin-3 that drives the 
glycosphingolipid-dependent membrane bending at the initial steps of CLIC biogenesis (43).  
 
1.4.4 ARF6-associated pathway 
Another form of NCE is the highly conserved, dynamin independent, ADP-ribosylation factor 
6 (ARF6)-associated pathway (44). Cargoes internalized trough this endocytic route are 
different and can be divided into proteins involved in: i) nutrient and ion transport (Glut1, 
CD98, Lat1); ii) matrix interaction (CD44, CD147); iii) immune response (MHC class I, 
CD1a); and iv) GPI-anchored proteins (CD55 and CD59) ((45) and reviewed in (46)). 
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Interestingly, after internalization, cargoes entering into this route undergo distinctive sorting. 
For example, CD55 and Glut1 follow MHCI internalization and can be found in EEA1-
positive endosomes, where also transferrin is present, whereas CD44, CD98 and CD147 do 
not enter the EEA1-positive compartment; however, the fate of all cargoes internalized 
through this pathway is mainly recycling (45).  
 Some of the cargoes internalized through the Arf6-positive pathway are the same as 
the CLIC-GEEC, however, in cells where this pathway is active, Arf6 ablation has only a 
minor impact on internalization, suggesting that Arf6-positive and the CLIC-GEEC are 
distinct endocytic routes sharing some of the molecular players (1). 
 
1.4.5 IL-2 receptor endocytic route 
The Interleukin-2 receptor (IL-2R) is internalized through another class of NCE pathways that 
is characterized by small non-coated PM invaginations (50-100 nm). IL-2 receptors are 
associated predominantly with detergent-resistant membrane domains (DRMs). The 
association with DRMs is triggered by IL stimulation and maintained alongside early steps of 
endocytosis. Endocytosis of IL-2R specifically occurs at the level of membrane protrusion 
rather than at the level of  ‘flat’ PM (reviewed in (47)).  
The molecular machinery underlying the endocytosis of the IL-2R has been 
characterized (48,49), starting from the requirement of dynamin and RhoA to complete the 
internalization (50). Activated IL-2R triggers the PI(3)P (phosphatidylinositol 3-phosphate) 
signaling cascade, which then activates RhoA and Rac1, followed by the activation of p21-
actiavted kinase 1 (Pak1) by Rac1. Pak1, in turn, phosphorylates cortactin that, together with 
neuronal Wiskott-Aldrich syndrome protein (N-WASP), promotes the formation of F-actin, 
which is needed for the completion of the endocytic process (49). 
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1.4.6 Fast endophilin-mediated endocytosis (FEME) 
A new route belonging to the category of NCE pathways has recently been described. This 
pathway relies on the rapid formation of tubulo-vesicular endocytic structures that depend on 
endophlin A proteins (A1, A2, A3), hence the name: fast endophilin-mediated endocytosis 
(FEME). Endophilins were already known to be peripheral players involved in clathrin-
mediated endocytosis, although the triple KD of endophilin A1-3 does not completely block 
endocytosis of the CME cargo transferrin (51). Endophilins possess a SH3 domain through 
which they interact with cargo receptors, and a BAR domain to induce membrane curvature. 
The morphology of FEME is similar to the morphology of CLIC; however, FEME needs 
dynamin for its execution (dispensable for CLIC-GEEC), Rac, phosphatidylinositol-3-OH 
kinase, Pak1 and actin polymerization. Moreover, different from CLIC, FEME is negatively 
regulated by Cdc42 and is upregulated in its absence (52). 
FEME mediates the ligand-triggered internalization of many cargoes: different G-
protein-coupled receptors such as α2a- and β1-adrenergic, dopaminergic D3 and D4 receptors 
and muscarinic acetylcholine receptor 4; the receptor tyrosine kinases EGFR, HGFR, 
VEGFR, PDGFR, NGFR and IGF1R, as well as the interleukin-2 receptor.  
This new pathway is prevalently working at the leading edge of migrating cells 
(Figure 7): in particular, endophilins are recruited at the level of lamellipodia by the formation 
of phosphatidynlinositol-3,4-bisphosphate (PI(3,4)P2) by SHIP phosphatases. Thus, FEME 
may be required for large PM rearrangement required during cell migration.  
The FEME pathway mediates also the entrance of cholera and shiga toxins (STx), two 
famous cargoes that enter the cell through a clathrin-independent pathway (53). Endophilin 
A2 (endo A2) recognize a highly curved membrane domain, and is involved in the pinching 
step of FEME structures, as a consequence of its role, endoA2 ablation causes an elongation 
of STx-containing structures. The complete block of STx internalization, however, was 
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observed only after simultaneous ablation of endo A2, actin and dynamin, which act in 
concert in the execution of this pathway (53). 
 
Adapted from Boucrot, Nature, 2015 (52) 
Figure 7. Endophilin requirement at the leading cell edge.  
A model of endophilin-dependent (FEME) endocytosis at the leading cell edge. Endophilin-
coated vesicles/tubules associate with receptors or receptor-adaptors (like CIN85/Cbl) 
through their SH3 domains and promote membrane curvature through their N-BAR domains. 
Dynamin is recruited by endophilin and is required for the last step of detachment from the 
PM.  
 
 1.5 Dynamin: a master regulator of membrane trafficking 
The GTPase dynamin is required for the completion of numerous endocytic pathways: CME, 
caveolae-mediated endocytosis, IL2-R endocytosis and FEME. Based on its function in 
several endocytic pathways, dynamin can be described as a master regulator of membrane 
trafficking. Dynamin intervenes in endocytosis at the moment of the detachment of endocytic 
structures from the PM when membranes are already in close apposition at the level of the so-
called ‘neck’ of endocytic intermediates.  
The first time that dynamin was associated with endocytosis was in a study of a 
temperature-sensitive mutant of shibire, the dynamin homologous in Drosophila 
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melanogaster (D. melanogaster). This mutant caused paralysis in the model system due to 
alteration in the release of synaptic vesicles (54). Further studies confirmed the fundamental 
role of dynamin in endocytosis, often assessed with the expression of the dominant negative 
K44A GTPase mutant. The expression of the dominant negative form of dynamin does not 
stop the formation of clathrin pits but causes the formation of elongated structures. A similar 
phenotype is observed upon complete ablation of dynamin, suggesting not only that dynamin 
is involved in the process, but that is also required for the last step of the pinching off. Indeed, 
in some cases, prior to dynamin action, actin and BAR proteins, like endophilins, are 
necessary for the stabilization of the neck of the endocytic structure (18,52,53). For instance, 
in cells in which the PM tension is reduced, actin is required for the stabilization of clathrin 
pits prior to dynamin action, otherwise, the GTPase cannot complete the pinching of the 
endocytic structure from the PM (55). 
Mammalian cells possess three dynamin genes that encode for three proteins that share 
80% homology but are differently expressed. Dynamin 1 is expressed at high levels in 
neurons; dynamin 2 is ubiquitously expressed; dynamin 3, like dynamin 1, is prevalently 
expressed in the brain, but also in testis and to a lower extent in lungs (56). 
Invertebrates like C. elegans and D. melanogaster possess only a single gene for 
dynamin, so the existence of three genes in mammals could suggest a specific role for the 
different isoforms embedded in their different binding proprieties rather than related to 
different expression levels.  
Dynamin possess different domains (Figure 8a):  
- N-terminal GTPase,  
- middle region: needed for the dimerization, 
- pleckstrin homology (PH): binds phospholipids, especially PI(4, 5)P2  
- GED: GTPase effector domain 
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- proline rich C-terminus domain (PRD): interacts with SH2 domain containing 
proteins. 
To execute its function, the dynamin monomer dimerizes through the middle region 
with the N-terminal domain oriented in the opposite direction and combined to form tetramers 
(Figure 8b). The tetramers then oligomerize in a helical polymer at the neck of vesicles at the 
PM, and, through constriction induced by torsion, fuses the two sides of the neck, leading to 
vesicle separation from the PM (Figure 8c-d). To execute these functions, dynamin needs to 
hydrolize GTP through its GTPase domain (56). 
 
 
 
 
 
 
 
 
 
 
Adapted from Ferguson Nat Rev Mol Cell Biol. 2012 (56) 
Figure 8. Dynamin structure and function.  
a) Representation of the domain organization of dynamin.  
b) Schematic representation of dynamin dimers.  
c) Proposed GTP hydrolysis-dependent movement of dynamin neck leading to dynamin-
mediated membrane fission.  
d) Cryo-electron microscopy image showing a helical polymer of purified dynamin that has 
driven the formation of a tubule from a liposome.  
 
 
a
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1.6 After endocytosis: sorting at the endosomal level 
Stereotypical view of the endosomal compartment strictly divided the endosomes into early, 
late and recycling endosomes. This view, however, has been revised towards a more dynamic 
picture, showing that this compartment is highly active and responsible for the collection of 
internalized cargoes and sorting to final destination (57).  
The first feature that is used to categorize endosomes is the pH, which gradually 
decreases along with endosome maturation. This work is done by a v-type vacuolar H
+
 
ATPase, a transmembrane protein that pumps hydrogen ions into the lumen and decreases the 
pH. Considering the different pH sensitivity of ligand-receptors complexes, the decreasing pH 
is important for the regulation of the stability of the complexes. In particular, receptors that 
have to be actively recycled release the ligand already at pH 6.5, typical of early endosomes; 
while signaling receptors, like the EGFR, stay bound to their ligand and signal also at a lower 
pH, pH 4.5, typical of late endosomes.  
Trough the endocytic pathway, endosomes change also their phosphatidylinositol 
phospholipid (PIP) composition, PIP interconversion is regulated by lipid kinases and 
phosphatases that act at different levels of endosomes maturation (58). 
Endosomes are also characterized based on their association with different Rab 
GTPases, which are required for proper vesicle trafficking. Typical Rabs for the early 
endosomes are Rab4 and Rab5. These proteins recruit GEFs to endosome, which in turn 
recruit and activate Rabs in the following compartment (59,60). Following endosome 
maturation, Rab5 is lost and contemporary substituted by Rab7 (61). The Rab7 GTPase is 
active at the level of late endosomes that, while going through multivesicular bodies (MVBs), 
leads to cargo degradation in the lysosome. Rab11, instead, is enriched at the level of 
recycling endosomes and drives receptors back to the PM.  
An example of the emerging plasticity of the early endosomal compartment is a recent 
model that revised the role of APPL-marked endosomes. More in detail, early endosomes are 
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marked not only by Rab5 but also by its effectors EEA1 and APPL1. APPL proteins seem to 
interact specifically with some types of receptors, and APPL endosomes have been 
considered to be intermediate structures for all endosomes before the acquisition of EEA1. 
Recently, new data highlights the possibility that multiple populations of endosomes coexist, 
one positive for APPL, one positive for EEA1 and one positive for both. Interconversion 
between the compartments is possible (57).  
Once internalized, cargo fate is determined by sorting signals in its sequence (62) or 
by post-translation modifications, like ubiquitin, as in the case of EGFR ((63) and section 
3.1.3). The different sorting of internalized cargoes is regulated also by the geometry of early 
endosomes. Indeed, the diverse shapes of the endocytic structures can facilitate the 
accumulation of cargoes for degradation or redistribution at the PM (64).  
Sorting of endosomes is regulated by the ESCRT (endosomal sorting complex 
required for transport) machinery. This complex consists of four protein complexes: ESCRT-
0, -I, -II and -III, according to their consecutive involvement in the sorting of cargoes into 
MVEs (for a recent review see (65)). The first three protein complexes contain ubiquitin-
binding subunits and are responsible of the recognition of ubiquitinated cargoes. ESCRT-III, 
instead, forms oligomers and is involved in the interaction with deubiquitinating enzymes that 
are involved in the release of ubiquitin from the cargo before degradation. The ATPase VPS4 
is then recruited and dissociate ESCRT-III oligomers for subsequent reuse (66,67). 
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2. Endocytosis and signaling 
Cells have developed fine-tuned systems to regulate signaling. One of these systems is 
endocytosis and trafficking of PM receptors. The first line of control is represented by the 
regulation of the number of receptors exposed at the PM. This view is, however, simplistic, 
indeed, depending on the kind of receptors and on the endocytic route, signaling can continue 
along the endocytic pathway. Moreover, the spatial constrains of receptors into endosomes 
add another line of control, spatially defining the source of signaling.  
 
2.1 Signaling from the PM 
After ligand binding, PM receptors are usually removed through endocytosis in order to 
regulate the magnitude of the signal coming from their activation. If the ligand administration 
is prolonged over time, in some cases, like for example RTKs, the number of receptors at the 
PM is permanently reduced and can results in downmodulation of signaling but can also shift 
ligand concentration to higher levels to obtain the same magnitude of signal (68). 
Signaling starts at the PM level and cargo clustering is often required to orchestrate a 
productive signaling. This is the case of RTKs and GPCRs, for which cargo clustering is 
absolutely required (69,70) (see (71) for a recent review). Cargo clustering can be regulated 
by the dynamics of pit formation. For example, the time of pit establishment can determine a 
different output in the case of cannabinoid receptor 1 (CB1R); thus regulating β–arrestin 
signaling. Depending on the type of ligand, endocytosis occurs through CCPs with different 
dwell times. In particular, pits that are formed in a fast process, stimulated by the agonist 
WIN 55,212-2, do not lead to the production of an active signal, while pits that are formed in 
slow process or in a prolonged period of time, stimulated by the ligand 2-AG, lead to 
productive clustering and, thus, to strong signaling (72) (Figure 9a).  
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CCP dynamics can be regulated not only by the internalized cargo but also by the lipid 
composition of the membranes involved. Indeed, some specific lipids are substrates for 
enzymes like phospholipase C (PLC), which is able to work only in the presence of the 
specific lipid substrate. PLC requires the presence of PI(4,5)P2 (phosphatidylinositol 4,5-
bisphosphate) and PI(3,4,5)P3 (phosphatidylinositol 3,4,5-trisphosphate); and, for example, in 
the case of EGFR, PLC is active at the level of the PM, which is enriched in PI(4,5)P2, while 
it is almost completely inactive at endosomes where PI(4,5)P2 is virtually absent (73,74). 
Signaling from the PM is also crucial for migrating cells. The localization of receptors 
in specific areas of the PM, as the leading edge, is required for a proper localization of 
signaling that, in turn, is crucial in the chemotactic response of the cell. Indeed, ligand 
sequestration at the leading edge provides spatial localization of signaling towards the 
migrating front, renders it less available for receptors at the lateral side; and through 
degradation of activated receptors cells are progressively less sensitive to the stimulus until a 
complete stop of migration occurs ((75), for a review see (76)).  
Notch signaling is an example of the importance of endocytosis in the regulation of 
ligand and receptor exposure on the PM (reviewed in (68)). The signal regulation of this 
pathway involves the interaction between the membrane-bound ligand (e.g., Delta) on the so-
called ‘signal sending cell’ and the receptor (Notch) on the ‘receiving cell’. Importantly, a 
recent study uncovered that Notch signaling from the PM can be regulated also by physical 
stimuli like temperature and mechanotension (77). Two different routes for Notch 
internalization are present during the development of D. melanogaster: at low temperature, 
Notch is constitutively internalized through a cholesterol-independent pathway that leads to 
signal activation; while at higher temperatures, a cholesterol-dependent way is prevalently 
activated and leads to the degradation of Notch ((77), Figure 9b).  
PM tension is another feature that can regulate endocytosis and subsequent signaling; 
conversely, endocytosis, through the alteration of membrane composition, can modify PM 
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tension. This bidirectional regulation is particularly important when cells communicate with 
the extracellular matrix (ECM), a process that requires the active regulation of integrin 
signaling. In particular, the diverse rigidity of the ECM is able to regulate the recruitment of 
different adaptors or endocytic machineries necessary for endocytosis (78).  
Adapted from Barbieri et al. Current Opinion in Cell Biology 2016 (79) 
 
Figure 9. Endocytosis controls signaling from the PM.  
a) Left, the agonist WIN 55,212-2 induces recruitment and internalization of the cannabinoid 
receptor (CB1R) through CCPs, which results in trimeric G-protein (α, β, γ)-mediated 
signaling, but fails to generate productive β-arrestin-dependent signaling. Right, the agonist 2-
AG recruits CB1R into CCPs with slow dwell times allowing for both G-protein and 
productive β-arrestin-dependent signaling, which leads to the phosphorylation of Erk1/2 and 
cell proliferation.  
b) Physical and mechanical stimuli, like temperature (left) or PM tension (right), control 
endocytosis and signaling. Left, in D. melanogaster, Notch is constitutively internalized, 
mainly via Deltex-mediated endocytosis, at low temperatures. At higher temperatures, Sudex-
mediated endocytosis is enhanced and leads to Notch degradation. Right, under low PM 
tension (top), assembly of the clathrin coat is sufficient to deform the PM. Bottom, under high 
PM tension clathrin assembly is unable to counteract the tension force, and invaginations 
pause until actin polymerization provides the energy. In this second case, CCPs have an 
extended lifetime, which is necessary to allow Hip1R to be recruited and for actin 
polymerization to occur. 
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2.2 Signaling from endosomes 
It is now clear that endocytosis does not block signaling after the removal of receptors from 
the PM; indeed, signaling can continue at the endosomal level, allowing a sustained phase of 
the signaling response (80). Moreover, endosomes can be seen as “signaling platforms” that 
organize and orchestrate specific downstream signaling pathways. Different features of 
endosomes make this compartment ideal for the regulation of signaling: 
i) a small volume that favors the interaction between ligand and receptor, 
ii) a prolonged time for activated receptor to signal, 
iii) a peculiar microenvironment that can regulate receptor activity, 
iv) mobility inside the cell. 
Another level of regulation that can arise from endosomes is through the control of the 
number of endosomes, through which a cell can obtain the conversion of an analogical signal, 
like the concentration of a ligand, into a digital signal, like a specific cell response. This was 
shown for signaling receptors like EGFRs, which are not randomly distributed into 
endosomes but packaged in precise quantities into endosomes. The number of EGFR-
containing endosomes, not the number of receptors per endosome, is increased with 
increasing EGF concentrations; this type of packaging in quanta allows an analog-to-digital 
conversion, from ligand concentration to signaling, and confers robustness to signaling which 
is actively regulated (81). Apparently, this control system is not restricted to EGFR signaling 
but is active also for hepatocyte growth factor receptor (HGFR) and nerve growth factor 
receptor (NGFR) (81). Importantly, the organization of receptors into endosomes defines a 
scaffolding role for these structures. At this level, signaling receptors can interact with 
adaptor proteins that are needed for the activation of downstream signaling, like growth factor 
receptors that activate the MAP kinase signaling.  
An example of the flexibility that endosomes can give with their movement inside the 
cell is the regulation of cAMP signaling downstream GPCRs. After ligand-induced activation, 
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these receptors couple with G proteins and stimulate adenylyl cyclase that produces cAMP, 
which in turn regulates downstream effectors. In the case of β2-AR, after activation, receptors 
are internalized into endosomes and are physically moved from the PM to the nucleus, where 
the production of cAMP is locally required for an efficient control of transcription (82). 
 
2.3 Endocytic routes and receptor fates 
Signaling coming from receptor activation is regulated not only by the internalization of 
receptors into endosomes, but also by the kind of endocytic route through which they are 
internalized. Several receptors, like RTKs, GPCRs, TGFβR (tumor growth factor β receptor), 
Notch and Wnt, are internalized both through CME and NCE and the entrance into these 
pathways is finely regulated and results in different output (68).  
The Wnt signaling pathway is fundamental for development regulation due to its 
regulation of the activation of β-catenin that, upon binding of transcription regulators, 
determines the activation of genes needed for cell proliferation. This system is finely tuned 
thorough the activation of two diverse endocytic routes. The transmembrane receptor Frizzled 
(Fz), upon binding with its ligand Wtn3a clusters with the co-receptor LRP6 (low density 
lipoprotein receptor-related protein 6), and through the interaction with Dishevelled (Dvl) and 
Rab8, promotes the internalization through the NCE caveolae pathway. This route is 
associated with β-catenin accumulation and, thus, with proliferation. When the Wnt3a agonist 
Dickkopf (DKK) is present, instead, it binds LRP6 and moves its internalization to the 
clathrin-mediated pathway, resulting in an increased β-catenin degradation and signal 
attenuation ((83) and Figure 10).  
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Adapted from Barbieri et al. Current Opinion in Cell Biology 2016 (79)  
Figure 10. Different endocytic routes and different fates.  
WNT3a binding to its receptor Frizzled (Fz) induces the interaction with LRP6, Dishevelled 
(Dvl) and Rab8, and mediates internalization through caveolae. This allows β-catenin 
accumulation and leads to cell proliferation. In contrast, the Wnt pathway antagonist DKK1 
recruits LRP6 to clathrin-mediated endocytosis (CME), which ultimately leads to β-catenin 
degradation and signal extinction.  
 
 
In the case of TGFβR and EGFR, the regulation is the opposite to that of LRP6. Upon 
ligand binding, TGFβR is activated and initiates the Smad signaling, for which the interaction 
with the Smad adaptor SARA (Smad anchor for receptor activation) in endosomes is 
important, which in turn interacts with PI3P. The characteristic of the regulation of this 
receptor through endocytosis is that signaling starts when TGFβR is internalized through 
CME, but undergoes ubiquitination and degradation when it is internalized through NCE, 
apparently through caveolar structures (84). A similar regulation is exerted on the endocytosis 
of EGFR ((63) and see section 3.2).  
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3. EGFR endocytosis and trafficking 
EGFR, also called ErbB1, belongs to the ErbB family of RTKs, which includes 
ErbB2/HER2/Neu, ErbB3/HER3 and ErbB4/HER4 (85,86). These receptors are characterized 
by a large extracellular ligand-binding region composed of  ~620 amino acids, a single 
membrane spanning α-helix, and a ~550 amino acids intracellular region that contains a 
juxtamembrane portion (composed of ~45 amino acids), followed by the tyrosine kinase 
domain (~270 amino acids) and the C-terminal regulatory sequence (~230 amino acids). Upon 
activation, the ErbB receptor undergo dimerization and autophosphorylation in trans in the C-
terminal tail. This signal triggers the recruitment of downstream signaling proteins with a SH2 
(Src homology 2) or a PTB domain that start the downstream signaling network (87) . 
 
3.1 EGFR activation 
3.1.1 EGFR dimerization  
In the extracellular region, each single monomer of EGFR presents four subdomains, named 
subdomains I-IV.  
- Subdomains I and III (Figure 11) are homologous and form the site where the ligand is 
bound.  
- Subdomains II and IV (Figure 11) are also homologous, and are characterized by a 
high cysteine content (88). 
When the ligand is not present, the EGFR extracellular region adopts a close configuration; in 
this condition, the subdomain II is tethered with subdomain IV (Figure 11a). Without ligand, 
only a minor part of the monomers is found in an “open conformation” (Figure 11b). EGFR 
monomers continuously alternate their status as monomers and dimers. Only upon ligand 
binding the open conformation is stabilized (Figure 11c) and the dimerization interfaces in 
subdomains II and IV are exposed, leading to proficient dimerization (88) (Figure 11d).  
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Adapted from Lammerts van Bueren JJ PNAS, 2008 (89) 
Figure 11. Lligand-induced EGFR activation.  
EGFR domains are shown (domain I, blue; domain II, green; domain III, yellow; domain IV, 
red; intracellular tyrosine kinase domain, gray).  
a) Unbound monomer of EGFR in tethered conformation.  
b) EGFR in “untethered” conformation.  
c) A ligand binds an untethered ligand and interacts with domains I and III, stabilizing the 
extended form.  
d) Dimerization of two monomers through interaction of domain II. The intracellular kinase 
domains cross-phosphorylate residues in the C-terminal receptor tail.  
 
 
EGFR dimerization is a crucial step in receptor activation and controls the kinase 
activity of the receptor, which is regulated by autoinhibition. The receptor is activated by an 
intermolecular allosteric interaction only upon dimerization induced by the ligand. In the 
kinase domain of an active EGFR, the C-lobe of one monomer (the activator) takes contacts 
with the N-lobe of the other monomer (receiver), leading to the reversion of the auto-
inihibitory interaction in the receiver monomer (90). 
 EGFR activation appears to be regulated also by the intracellular juxtamembrane 
region. Indeed, this segment is required to potentiate dimerization and to make the activation 
mechanism operative (91,92). To complete the activation of the receptor upon ligand binding, 
a b c d 
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also the calcium binding protein calmodulin appears to be crucial. Indeed, the EGFR 
juxtamembrane region possesses a positively charged calmodulin binding domain (CaM-BD) 
that in resting conditions is bound to the negatively charged inner leaflet of the PM (Figure 
12), leading to auto-inhition in the absence of ligand. EGF stimulation leads to an increase in 
calcium levels and to the binding of calcium to calmodulin, forming the Ca
2+
-calmodulin 
complex. One hypothesis is that the interaction with the calcium-bound calmodulin facilitates 
the detachment of the juxtamembrane region of EGFR from the PM, thus leading to the 
complete activation of the receptor (Figure 12) (93,94)  
Adapted from Stateva, Biochem Journal, 2015 (94) 
Figure 12. Calmodulin regulation of EGFR activity.  
In resting conditions, both the CaM-BD and the tyrosine kinase domain (TK) of the EGFR are 
electrostatically bound to the inner leaflet of the PM. When calmodulin is not bound to 
calcium (apo-CaM), it can tether to the receptor close to its TK. After ligand binding, the 
cytosolic concentration of free Ca
2+
 is high enough and Ca
2+–CaM complexes are formed and 
bind to the CaM-BD of the EGFR that is completely detached from the membrane, thus 
activating the receptor.  
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3.1.2 The EGFR signaling cascade 
EGFR can be activated by different ligands: EGF, TGFα (transforming growth factor α), HB-
EGF (heparin-binding EGF-like growth factor), betacellulin, epiregulin, amphiregulin, and 
epigen. All these ligands have a so-called EGF-motif, which consists of six cysteine residues 
that interact through disulfide bonds (95). EGF and TGF α are specific ligands for EGFR. 
After activation, EGFR can start different downstream signaling pathways; the major ones 
are: 
(1) PLC γ (phospholipase C γ), which in turn activates PKC and a calcium cascade, 
(2) Ras signaling, leading to various MAPKs, 
(3) PI3K, leading to AKT signaling cascade.  
The final output of these signaling cascades are different and comprise: proliferation, 
migration, and differentiation (87). Considering the important effect of this signaling cascade 
on cell fate, the process is highly regulated through post-translational modifications and 
receptor endocytosis (for a review see (96)). 
 
3.1.3 EGFR phosphorylation and ubiquitination 
Upon ligand binding, the EGF receptor undergoes auto-phosphorylation in correspondence 
with tyrosine residues present at the C-terminus and phosphorylates different cytoplasmic 
substrates. There are several tyrosine residues on EGFR that serve as docking sites, among 
which:  
- Tyr1068 and Tyr1086, which are crucial for the recruitment of the adaptor Grb2 
(growth factor receptor-bound protein 2) that is involved in the Ras-MAPK signaling 
cascade (Figure 13) and in endocytosis ((97) and section 3.2.1); 
- Tyr1092, which is important for the interaction with PLC γ; 
- Tyr1173 and Tyr1148, which are required for the interaction with the adaptor SHC 
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Another crucial post-translational modification of the EGFR is ubiquitination. 
Ubiquitin (Ub) is a small, highly conserved, protein composed of 76 amino acids and is 
characterized by a di-glycine motif in which Gly76 can be conjugated by the ε-amino group to 
a lysine on a target protein. The modification of the target protein requires the intervention of 
three classes of enzymes: E1, E2 and E3 – E3 is the enzyme that covalently attaches the Ub 
molecule to the substrate.  
Ub can be attached as: (a) monoubiquitin, when one Ub moiety is attached to one 
lysine residue or (b) multimonoubiquitin, when many lysine residues are modified with a 
single Ub moiety, or (c) polyubiquitin, when a chain of Ub is attached. All seven lysine 
residues in a Ub molecule can be used for chain formation in vivo (98), although Lys11-, 
Lys48- and Lys63-linked chains are the most studied and the most abundant lysines in the cell 
(99). In particular, Lys63-linked polyubiquitin chains play, among others, important roles in 
endocytic trafficking (100). 
The major E3 ligase involved in ubiquitination of EGFR is Cbl (Figure 13) (101). 
Three Cbl genes have been identified in mammals: Cbl (also called c-Cbl), Cbl-b and Cbl-c. 
Cbl proteins have multiple domains:  
i) the tyrosine kinase-binding domain (TKB), which can directly bind to the 
phosphorylated Tyr1045 of EGFR,  
ii) the RING E3 ligase domain, 
iii) a proline rich region, through which interact with Grb2, 
iv) the UBA (ubiquitin associated) domain, responsible for Ub-binding and/or 
dimerization (102). 
The ubiquitination sites on EGFR have been mapped and the two major modifications 
that occur are monoubiquitination (~49% of the modified receptor) and Lys63-linked 
polyubiquitination (~40% of the modified receptor) in the kinase domain of the receptor 
(103). EGFR ubiquitination has a fundamental role in receptor endocytosis and in the 
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regulation of its intracellular fate. Indeed, when EGFR is stimulated with high dose of EGF, a 
substantial fraction of the receptor becomes ubiquitinated and is destined to lysosomes for 
degradation ((22) and section 3.2.2). 
 
Adapted from Polo, BMC Biology, 2012 (104) 
Figure 13. The interaction of Grb2 and Cbl with active EGFR.  
Upon EGF activation, Tyr1068, Tyr1086 and Tyr1045 residues in EGFR are phosphorylated, 
permitting the recruitment of the adaptor Grb2. Finally, the recruitment of Cbl leads EGFR 
ubiquitination.  
 
3.2 EGFR endocytosis 
A critical regulator of EGFR signaling is endocytosis. Depending on ligand concentration and 
cell context (68), EGFR internalization can occur both via CME and NCE. At low EGF doses 
(≤1 ng/ml), receptors are almost exclusively internalized through CME. In contrast, at high, 
yet physiologically relevant, EGF doses (20 - 100 ng/ml), a substantial proportion of EGFR 
(around 40% in HeLa cells) is internalized, in parallel to CME, also through NCE (63). 
Importantly, both low and high doses of EGF are physiological; indeed, EGF concentrations 
vary in different bodily fluids (Table 2):  
- low (1–5 ng/ml) in plasma, serum, and saliva,  
- medium (5–50 ng/ml) in tears, follicular fluid, sperm, and seminal plasma, 
- high (50–500 ng/ml) in bile, urine, milk, and prostate fluid. 
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Moreover, EGF can act as a juxtacrine stimulator as it is produced as a transmembrane 
precursor and is not always processed (especially in the kidney) (105). Thus, under 
physiological conditions, cells are exposed to a wide range of ligand concentrations but 
epithelial cells act as a barrier, preventing the encounter of EGF-containing fluids with EGF 
receptors expressed on the basolateral membrane of cells. In pathological conditions, 
however, like in lesions or in premalignant neoplasia, tight junctions of the epithelia become 
leaky and lead to elevated doses of EGF that reach and activate the EGFR. Moreover, high 
levels of EGFR ligands have been found in different cancer types (reviewed in (106)).  
 Tissue/bodily fluids Concentration 
 LOW 
Plasma 
Serum 
Saliva 
~1 ng/ml 
~5 ng/ml 
1-3 ng/ml 
   MEDIUM 
Tears 
Follicular fluid 
Sperm 
Seminal plasma 
10-30 ng/ml 
3-30 ng/ml 
20-40 ng/ml 
~50 ng/ml 
HIGH 
Bile 
Urine 
Milk 
Prostate fluid 
~150 ng/ml  
~100 ng/ml 
~400 ng/ml 
150 ng/ml 
 
Table 2. Different concentrations of EGF in human tissues and body fluids.  
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3.2.1 Clathrin-mediated endocytosis of EGFR 
CME is the best-characterized endocytic route for EGFR. Indeed, EGFR possess different 
sequence motifs in its C-terminal tail that interact with the clathrin adaptor AP2. More in 
detail, the receptor directly interacts with the μ2 subunit of AP2, and mutations in this motif 
do not block completely EGFR entrance through CME (107). Moreover, the removal of AP2 
reduces CME of EGFR, even if to a lesser extent compared to the removal of clathrin, thus 
suggesting the possible involvement of other adaptors ((108) and section 1.3.2). 
After ligand binding, the EGFR undergoes auto-phosphorylation (Tyr1068 and 
Tyr1086) and Grb2 is recruited to the receptor. The phosphorylation of these residues appears 
necessary for CME, as when they are mutagenized, Grb2 is no longer recruited to the receptor 
and CME of EGFR is strongly affected (97). Grb2 can interact with Tyr1068- and Tyr1086- 
containing motifs of the receptor (97,109) through its SH2 domain, coupling the receptor with 
other proteins. One of the major Grb2-interacting proteins is Cbl: different evidences 
highlight a function for Cbl in EGFR internalization. Cbl has been found to translocate to 
CCPs upon EGF stimulation (110). Expression of Cbl mutants inhibits EGFR internalization 
(97) and siRNA depletion of both Cbl and Cbl-b results in partial inhibition of receptor 
endocytosis (103). Cbl directly ubiquitinates EGFR, but receptor ubiquitination is not always 
required for its endocytosis: indeed, EGFR ubiquitination is not essential for CME (22,103) 
but is required for NCE (22). In particular, EGFR mutants that lack Tyr1045 (the site 
recognized by Cbl) or the ubiquitin acceptor sites, undergo almost normal internalization via 
CME (22,111). Importantly, even if EGFR ubiquitination is not essential for CME, the 
activity of Cbl is still needed, possibly because it can ubiquitinate other components of the 
clathrin machinery or it can work as an adaptor in CME.  
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3.2.2 Non-clathrin endocytosis of EGFR 
Opposite to CME, EGFR ubiquitination is absolutely required for NCE. Our laboratory 
demonstrated that, in HeLa cells, ubiquitination of EGFR occurs only upon stimulation with 
high doses of EGF and that this is coupled to the emergence of the NCE pathway (22,111). 
Ubiquitination is required for proper NCE; indeed, the EGFR mutant (Y1045F), which is 
poorly ubiquitinated, is defective for NCE but not for CME (111). Also other ubiquitin-
binding proteins, Eps15, Eps15R and Epsin, appear to be recruited to the ubiquitinated EGFR 
and are redundantly essential but not specific, due to their involvement also in CME, in 
EGFR-NCE (22).  
Ubiquitination is threshold controlled in different model systems and works as the 
molecular switch that triggers the internalization of EGFR through NCE (68). Ubiquitination 
is minimal at low doses and maximal at high doses of EGF, but presents a rapid increase in a 
narrow interval of EGF concentrations. EGFR-phosphorylation, instead, follows a typical 
hyperbolic dose-response curve (Figure 14). Thus, cells have the ability to convert a linear 
EGF signal into an on-off switch for the NCE system. By using a modeling approach, our 
laboratory demonstrated that a cooperative binding of Cbl and Grb2 to different 
phosphorylation sites on the EGFR tail is required for the proper control of this on-off system 
(112). Importantly, EGFR-NCE has been characterized in HeLa cells but its presence has 
been also verified in other cell lines, as reported in Table 3.  
 
 
 
 
 
 
Adapted from Capuani, EMBO Journal, 2013 (111) 
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Figure 14. EGFR phosphorylation versus ubiquitination.  
ELISA analysis of cell lysates after stimulation with the indicated doses of EGF and analyzed 
with anti-Ub or anti-pY antibodies. The results are presented as the percentage of the maximal 
tyrosine phosphorylation or ubiquitination (% of max). In black, the linear increase in EGFR 
phosphorylation. In red, the threshold behavior of EGFR ubiquitination. 
 
 
Cell line (EGFRs/cell) 
 
Low EGF Ke 
 
High EGF Ke obs 
 
NCE 
HeLa (3.0 x 10
5
) 
Control 
Clathrin-KD 
Dynamin KD 
 
0.30 
0.08 
0.07 
 
0.15 
0.08 
0.03 
 
 
 
Yes 
A431 (1.4 x 10
6
) 
Control 
Clathrin-KD 
  Dynamin KD 
 
0.42 
0.07 
0.08 
 
0.05 
0.03 
0.01 
 
 
 
Yes 
MDA MB-231 (0.8 x 10
5
) 
Control 
Clathrin-KD 
  Dynamin KD 
 
0.24 
0.04 
0.03 
 
0.19 
0.08 
0.02 
 
 
 
Yes 
BT20 (4.3 x 10
5
) 
Control 
Clathrin-KD 
  Dynamin KD 
 
0.10 
0.03 
0.03 
 
0.06 
0.04 
0.02 
 
 
 
Yes 
MCF10A (2.9 x 10
5
) 
Control 
Clathrin-KD 
  Dynamin KD 
 
0.27 
0.04 
0.02 
 
0.19 
0.02 
0.04 
 
 
 
No 
HCT116 (0.5 x 10
5
) 
Control 
Clathrin-KD 
  Dynamin KD 
 
0.23 
0.04 
0.04 
 
0.24 
0.05 
0.05 
 
 
 
No 
BT549 (0.5 x 10
5
) 
Control 
Clathrin-KD 
  Dynamin KD 
 
0.23 
0.04 
0.04 
 
0.13 
0.02 
0.02 
 
 
 
No 
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Table 3. The presence of NCE in different cell lines.  
The presence of EGFR-NCE was evaluated by comparing the internalization rate of EGF at 
low and high dose in WT versus clathrin-KD and dynamin-KD cells.  
 
3.2.3 EGFR internalization: two routes, two distinct fates 
In HeLa cells, CME and NCE of EGFR are linked to two different intracellular fates: EGFR 
molecules internalized through CME are mainly recycled back to the PM (70%), resulting in 
sustained signaling, while EGFRs internalized through NCE are selectively trafficked to 
lysosomes for degradation (90%), leading to signal attenuation (Figure 15, (63)). Thus, NCE 
appears to be required for suppressing EGFR signaling in response to excessive stimulus and 
might therefore represent a crucial safety mechanism by preventing overstimulation of the 
cell. Considering the frequent over activation of EGFR signaling in cancer, a thorough 
understanding of NCE could lead to novel insights into tumorigenesis.  
 
Adapted from Barbieri et al. Current Opinion in Cell Biology 2016 (79)  
Figure 15. The effect of CME and NCE on EGFR fate.  
At low doses of EGF, 90% of EGFR is internalized via CME and is targeted for recycling and 
sustained signaling, thus resulting in cell proliferation. At high doses of EGF, EGFR become 
significantly ubiquitinated concomitantly with the activation of NCE. NCE targets 
internalized EGFR mainly to degradation in the lysosome, leading to signal attenuation. 
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4. The endoplasmic reticulum: a multifunctional highway 
In recent years, the endoplasmic reticulum (ER) is emerging more and more as a central 
system, fundamental in the regulation of different processes. One of the most intriguing 
characteristic of this endomembrane system is that it is spread all over the cytoplasm of a cell 
and is able to reach every corner of it. Being so spread, the ER can come into close proximity 
with many different compartments of the cell and functionally interact with these. In recent 
years, the study of contact sites that regulate the interaction of the ER with different 
organelles has evolved, opening a new field of membrane contact sites (MCS).  
Contact sites are defined as any place inside the cell where organelles come into close 
contact with each other without membrane fusion at a distance of 20-30 nm (113). Thanks to 
its structure, the ER comes into contact with many organelles inside the cell; the first types of 
interactions studied were with mitochondria and the PM (113). In the past decade, many other 
contact sites between ER and other organelles have been revealed (114) and represent a new 
interesting field of study (Figure 16). Contact sites represent an ideal platform where 
organelles can exchange information and material. Indeed, MCS appear to be involved in the 
movement and positioning of organelles inside the cell and in the exchange of calcium and 
lipids ((114-116), and sections 4.2, 4.3). 
The ER system is divided into “rough endoplasmic reticulum” that represent the part 
of ER that is enriched in ribosomes, for protein synthesis, and that is more close to the 
nucleus; and “smooth ER” tubules that spread into the cell, are associated with less 
ribosomes, and constitute a “tubular ER network” that is able to stabilize contact with other 
organelles. In the next sections, the role of the crosstalk between tubular ER and endosomes 
will be discussed. 
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Adapted from Phillips Nature Reviews 2016 (114) 
Figure 16. Endoplasmic reticulum and membrane-contact sites (MCSs).  
The ER starts from the nuclear envelope (dashed line) and continues as peripheral ER, which 
diffuses into the cytosol as a network of sheets and tubules. Peripheral ER (smooth ER) forms 
MCSs with the PM, mitochondria, endosomes, peroxisomes, lipid droplets and the Golgi 
complex. 
 
 
4.1 ER in the regulation of endosome dynamics  
4.1.1 ER contact sites control endosome trafficking  
Endosomes are engaged by the tubular ER and travel inside the cell by following the ER 
network, maturing along the way. This association is maintained thanks to the formation of 
functional MCS between endosomes and the ER, and increases with the maturation of 
endosomes. Indeed, it has been calculated that 55% of early endosomes are associated with 
the ER while this percentage increase to 99% for late endosomes (117). 
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The system that regulates endosome dynamic is starting to be better defined. The level 
of cholesterol, for example, is one feature that regulates this process. In particular, when 
cholesterol levels are low, late endosomes accumulate at cell periphery; while high cholesterol 
levels lead to the localization of endosomes close to the cell center (118). This control is 
exerted by the protein ORP1L (oxysterol-binding-related protein 1L), a regulator that is 
localized at the membrane of late endosomes and possesses an oxysterol-binding related 
domain (ORD) through which it interacts with sterols (118). When the ORD domain interacts 
with cholesterol, ORP1L changes its conformation and is able to enter in a Rab7-containing 
complex that directs the endosome towards the cell center. In the absence of cholesterol, 
ORP1L interacts, instead, with the ER-localized protein VAP (Vamp-associated protein). The 
interaction with VAP drives endosomes preferentially towards the cell periphery (119,120). 
Another protein involved in endosome trafficking that is able to bind both Rab7 and 
VAP is protrudin. This protein is embedded into ER membranes and interacts with: VAP, 
PI3P, which is enriched at the level of late endosomes, and with the microtubule motor 
protein kinesin-1. At the level of MCS, protrudin, from the ER, interacts with Rab7 and 
PI(3,4,5)P3 in late endosomes; this interaction leads to the translocation of kinesin-1 from 
protrudin to the motor adaptor at the level of late endosomes. The kinesin-1 handover is a 
crucial step for the subsequent movement of late endosomes on the microtubule network 
(121). Deregulation of protrudin levels results in an alteration of endosome positioning: 
overexpression of protrudin and Rab7 causes an accumulation of late endosomes at the 
periphery, while protrudin depletion causes endosome accumulation at the perinuclear level, 
suggesting an impairment in their motility.  
A recent discovery highlights an important function in endosome positioning also for 
an ubiquitin ligase located in the ER, the Ring finger protein 26 (RNF26). RNF26 has been 
defined as the “global architect of the entire endosomal system” (122). RNF26 is an ER 
resident protein that exposes its RING domain into the cytosol, and through this domain 
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interacts and ubiquitinate the scaffold p62/sequesosome 1 (SQSTM1). This modification 
leads to the interaction with endosome adaptors that possess an ubiquitin-binding motif, 
leading to the “binding” of endosomes to the ER. The interaction between endosome adaptors 
and the ER allows the formation of the so-called “cloud” of endosomes at the level of the 
perinuclear area. This system is reversible and is regulated by the deubiquitinating enzyme 
(DUB) USP15 that, by removing ubiquitin from SQSTM1, allows the detachment of the 
endosome from RNF26 (122). 
 
4.1.2 ER contact sites control endosome fission and function 
The ER is involved not only in the spatial localization of endosomes, but also in the 
localization and timing of their fission. This event occurs both at the level of early and late 
endosomes. A recent study assessed the binding, in correspondence with MCS, of ER to 
endosomes, followed by endosome fission and defined that the ER remains bound to 
endosomes after the process (123). The actin machinery, bound to the WASH complex, the 
multiprotein complex that activate actin nucleation by Arp2/3, is required to terminate the 
fission process. On the contrary, microtubule polymerization seems to be required for the 
formation of contacts with endosomes-ER, but is not required for their maintenance or 
activity (123).  
A clear demonstration of the role of ER in endosome fission is the fact that alterations 
in ER shape, composition and dynamics result in a defective process in endosome fission 
(123). Recent evidences clarified the possible molecular mechanism involved in this process; 
MCS are platforms for the recruitment of all the factors necessary for the fission process and, 
considering the role of ER in lipid synthesis, the movement of lipids into the fission area is 
involved in the completion of the process (124). 
A clear role of ER-endosome contact sites has been defined for EGFR-positive 
endosomes. EGFR interacts with the protein tyrosine phosphatase PTB1B that is localized in 
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the cytoplasmic part of the ER. The EGFR needs to be endocytosed and transported inside 
endosomes to interact with PTB1B in correspondence with endosomes-ER MCS, as 
demonstrated by immune-electron microscopy (Figure 17 (125,126)). PTB1B regulates EGFR 
through dephosphorilation and acts, not only at the level of endosomes, but is also involved in 
the regulation of MVB maturation, thus promoting the sequestration of EGFR into MVB 
vesicles and leading to degradation and signal control (125). 
Of note, some evidences indicate an interaction of PTP1B with PM. This interaction 
highlights a function for contact sites between the ER and the PM in signaling control, at least 
in correspondence with cell-to-cell junction, where PTP1B can act, for example on EphA2 
(127). 
 
Adapted from Eden, Nature Cell Biology, 2010 (125) 
Figure 17. PTP1B endosomes create contact sites with the endoplasmatic reticulum.  
Cryo-immuno-EM of an endosome containing endocytosed EGF marked with gold EGFR and 
enwrapped by the ER. 
 
 
4.2 ER-endosome contact sites in the regulation of lipid exchange 
The ER synthetizes a vast number of phospholipids, sterols and precursor of sphingolipids 
that need to be moved to their active sites. However, the movement of lipids can occur also in 
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the other direction, from organelles to the ER, with the scope to control membrane lipid 
homeostasis (128). Independently of the direction, movement of lipids can be achieved by 
active transport through vesicles or through non-vesicular transport. An important role for 
MCS is emerging in this non-vesicular transport. The machinery involved in this process 
needs proteins that, with a hydrophobic pocket that allows the isolation of the lipid from the 
aqueous phase, are able to move lipids from one membrane to another. An example is the 
ORP5 protein, an ER transmembrane protein localized at late endosomes that is able to 
“accept” sterols from the protein NPC1 (Niemann-Pick C2 Protein) and to transfer them into 
the ER (129). Of note, ORP5 has recently been shown to be involved, together with ORP8, in 
the dual control of lipid composition of the PM and the ER. In particular, this protein 
mediates the movement of PI(4)P (phosphatidylinositol 4-phosphate) from the PM to the ER 
where the interaction with the phosphatase Sac1 leads to PI(4)P degradation. In the opposite 
direction, phosphatidylserine is moved from the ER to the PM where this lipid is enriched in 
specific domains (130). The ER-protein VAP, which controls the lipid composition of the PM 
and the ER, is crucial for the precise functioning of this system (124). 
 
4.3 ER-endosomes contact sites and calcium  
Calcium concentration [Ca
2+
] is tightly regulated inside the cell, and its movement across 
membrane interfaces propagates its signal throughout the cell. The ER represents the major 
calcium store inside the cell, and calcium concentration in this organelle is between 60 and 
500 μM (114). Calcium concentration outside the cell is around 1 nM, and endosomes, 
considering that they are generated from the PM, start with a similar concentration that goes 
from around 1nM in newly formed endosomes to 2.5 μM in late endosomes. Different 
mechanisms intervene to precisely control calcium concentration inside different organelles 
(114). 
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The most characterized pathway used by the ER to release calcium occurs through the 
opening of inositol-1, 2, 3-trisphosphate receptor (IP3R) that is present in the ER membrane. 
The signaling cascade that leads to the opening of these channels starts at the PM, where 
external stimuli activate phospholipase C (PLC) that cleaves PI(4,5)P2, releasing cytosolic IP3 
that is necessary for the opening of IP3R on the ER membrane. The release of calcium from 
these receptors is massive and precisely localized but highly diffusible, and closely apposed 
membranes appear to be a favorite site for this type of calcium release (131,132). 
The release of calcium is not only directed from the ER but is also directed back to the 
ER itself. Indeed, endosomes can rapidly change their pH after their formation and release 
calcium as a “stimulus” to trigger more calcium release from the ER, suggesting a 
bidirectional regulation between these two organelles (114). 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Phillips, Nature Reviews, 2016 (114) 
Figure 18. Calcium (Ca
2+
) exchange at endoplasmic reticulum membrane contact sites. 
Ca
2+
 concentration [Ca
2+
] in different organelles is presented. 
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AIM OF THE PROJECT 
 
EGFR internalization via NCE is essential for receptor degradation in the presence of high 
EGF concentrations, safeguarding cells against excessive EGFR signaling. Since NCE 
appears to be a crucial negative regulator of EGFR signaling in response to excessive 
stimulus, we hypothesized that loss of this route could lead to aberrant EGFR signaling in 
cancer and that NCE could therefore be a novel tumor suppressor pathway.  
The aim of this thesis was to define the molecular mechanisms underlying EGFR-NCE 
by combining a candidate gene approach with an unbiased proteomic approach. Through 
high-resolution studies, we established that the EGFR-NCE pathway is distinct from other 
previously described clathrin-independent endocytic routes. We performed a proteomic 
analysis of NCE vesicles to identify NCE-specific regulators, and identified nine proteins 
with no previously defined role in endocytosis, four of which are ER proteins. Further 
investigation of one of these ER proteins, Reticulon 3 (RTN3), which is involved in the ER 
tubulation pathway, revealed that this protein is located in close proximity to active EGFR 
that internalizes via NCE, suggesting the existence of contact sites between the ER and the 
PM at sites of NCE. Thus, we set out to characterize the precise molecular mechanisms 
governing EGFR-NCE, taking advantage of RTN3 as a molecular tool, to elucidate the role of 
RTN3 in the crosstalk between the ER and the PM. 
Considering the regulatory role of EGFR-NCE, the definition of its molecular 
mechanism should provide insights into unexplored mechanisms of EGFR overactivation in 
cancer and could lead to the identification of novel cancer-relevant endocytic proteins that 
might represent useful tumor biomarkers or targets for therapeutic intervention.  
 
 
 59 
RESULTS 
 
1. Functional characterization of EGFR-NCE  
In order to characterize the EGFR-NCE pathway, we initially exploited a candidate gene 
approach, selecting players that have been described to have a fundamental role in clathrin-
independent endocytic routes.  
We analyzed the effect of Rac1 and Rac2, two GTPases involved in macropinocytosis; 
Cdc42 and GRAF1, two players mainly involved in the CLIC-GEEK pathway; RhoA, 
involved in IL-2Rβ
different non-clathrin endocytic cargoes like MHCI and MHCII (see “Introduction” for a 
more detailed description of these endocytic routes). To define the possible role of these 
players in EGFR-NCE, we followed EGFR internalization with iodinated 
125
I-EGF in HeLa 
cells upon knockdown (KD) of the candidate genes alone or in combination with clathrin KD.  
We assessed first EGF internalization upon clathrin and dynamin KD. Stimulation of 
HeLa cells with low dose of EGF (1 ng/ml) showed that ~75% of the ligand is internalized 
through CME, as represented by the inhibition of internalization upon clathrin KD or dynamin 
KD; the residual endocytosis could be due to an incomplete KD or due to the existence of a 
third pathway of internalization that is insensitive to clathrin/dynamin depletion, possibly 
representing the constitutive pathway of EGFR endocytosis (111). At high dose of EGF (30 
ng/ml), clathrin KD reduced the internalization only ~50%, while dynamin KD reduced the 
internalization ~80%; indicating that in these conditions clathrin KD is not sufficient for 
blocking EGF internalization due to an active NCE. Then, we assessed the role of the factors 
described above, both at high and low dose of EGF, in order to clarify whether they may have 
a specific role in EGFR-NCE. At high dose of EGF, Cdc42 KD and Rac 1/2 KD reduced EGF 
internalization ~20-50%. When the KD was combined with clathrin KD, we observed a 
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further reduction of ~80% of EGF internalization (Figure 19a, left).  These results indicate 
that Cdc42 and Rac 1/2 may be involved in EGFR-NCE. However, their role is not exclusive 
to this pathway as their KD blocks EGFR internalization also at low dose of EGF when NCE 
is not activated (Figure 19a, right). Note that Cdc42 KD and Rac 1/2 KD reduced EGFR 
internalization at low dose of EGF also when the KD was combined with clathrin KD, 
suggesting a more general role for these players in EGFR endocytosis, possibly also in the 
constitutive endocytosis of EGFR (Figure 19a, right). We did not score any significant effect 
on EGFR endocytosis upon KD of GRAF1 (Figure 19b), Arf6, RhoA and caveolin-1 (Figure 
19c) upon stimulation with high or low dose of EGF. The results obtained with caveolin-1 KD 
support our previous data that caveolin-1 KD does not affect EGFR degradation and signaling 
(63). 
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Figure 19. 
125
I-EGF internalization assays upon candidate gene ablation.  
a), b) and c) HeLa cells were transiently KD for the indicated proteins. Internalization 
constants (Ke) are plotted in the chart as % internalization compared to the control. High dose 
internalization rates (Ke obs) are plotted in the chart as % of the control. Red lines indicate 
the effect of clathrin KD and dynamin KD on 
125
I-EGF internalization. 
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1.1 EGFR-NCE is independent of endophilins 
The FEME pathway, a recently described novel clathrin-independent pathway, requires 
endophilin A proteins. This endocytic route is involved in the internalization of many PM 
receptors, including the EGFR, specifically in migrating cells (see also section 1.4.6, 
Introduction).  Thus, we tested the possible involvement of endophilin A (EndoA) in EGFR-
NCE.  
We initially tested the expression levels of the three endophilin A genes (A1, A2 and 
A3) in our HeLa cells by RT-QPCR analysis. We found that only endophilin A1 and 
endophilin A2 were expressed in our cells. Importantly, the KD of endophilin A1 and 
endophilin A2 did not have any significant impact on EGFR endocytosis, neither at low nor at 
high dose of EGF (Figure 20a,b). The combination of endophilin A1 and endophilin A2 KD 
with clathrin KD did not have any additive effect, suggesting that EGFR-NCE is functionally 
distinct from the FEME pathway (Figure 20a,b), at least in the model under scrutiny.  
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Figure 20. EGFR-NCE and endophilins.  
a) Low (1 ng/ml, left) and high (30 ng/ml, right) internalization assay in control and clathrin 
KD cells for endophilin A1/2 (grey bars). Controls are in black. Red lines indicate the effect 
of clathrin KD on 
125
I-EGF internalization.  
b) Left: efficiency of clathrin KD in the indicated samples was determined by IB. Tubulin 
was used as loading control. Right:  efficiency of endophilins KD in the indicated samples 
was determined by RT-QPCR and is represented as residual mRNA as a fraction of the 
control. 
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2. Molecular dissection of EGFR-NCE 
2.1 Unbiased proteomic approach to identify specific EGFR-NCE 
components 
Given the results above, we hypothesized that there might be unidentified, specific regulators 
of the EGFR-NCE pathway. To address this point, an unbiased approach was previously 
developed in our laboratory, based on the purification of NCE-EGFR vesicles in clathrin KD 
cells and on a quantitative mass spectrometry analysis using SILAC (Stable Isotope Labeling 
with Amino Acids in Cell Culture (133). From this analysis, we derived a list of 101 NCE 
candidates that were enriched in NCE-vesicles.  
 
2.2 Validation of the involvement of SILAC candidates in NCE 
To test the involvement of these candidates on EGFR-NCE, we performed KD of each single 
gene alone or in combination with clathrin and assessed its impact on EGFR internalization 
both at high (both CME and NCE are active) and at low dose of EGF (only CME is active) by 
125
I-EGF internalization assays. We also evaluated the possible effect of the candidate genes 
on EGFR surface number, as alterations in receptor number might affect the internalization 
rate of EGFR. To exclude the involvement of candidate genes in CME, we assessed if their 
ablation could have an impact also on Tf internalization, which occurs only through CME. 
The rationale for this screening is presented in Figure 21. 
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Figure 21. Flowchart of the unbiased screening and the validation procedure of NCE 
candidate genes.  
The 101 NCE candidates were selected from the SILAC list. The expression of these 
candidates was ablated, with a pool of four oligos, alone or in combination with clathrin KD, 
and the effect of the KD was assessed in 
125
I-EGF internalization assays at low and high dose 
of ligand. Also EGFR turnover was assessed. Deconvolution analysis resulted in the 
identification of 9 genes as regulators of NCE. The genes that scored "negative" in the initial 
round of validation were further analyzed and characterized by colocalization studies with 
internalized EGF, leading to the identification of a specific NCE cargo (see section 2.3). 
 
 
Nine bona-fide EGFR-NCE regulators were identified. These players have different 
functions, are involved in signal transduction, RNA-binding or are ER and mitochondrial 
proteins; none of them has previously been involved in endcocytosis. Importantly, these 
proteins are found associated with NCE vesicles and their ablation specifically blocks EGFR-
NCE but has no effect on CME. These EGFR-NCE regulators and their involvement in EGFR 
internalization are listed in Table 4. 
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Table 4. NCE functional regulators.  
The nine regulators of EGFR-NCE with their gene names and putative localization/function 
are presented in the table. For EGFR internalization, results are expressed as a reduction of 
the Ke of internalization compared to control (high dose of ligand). The effect of genes 
ablation alone or in combination with clathrin KD is reported. Mito: mitochondrial, bind: 
binding, sign: signaling, fin: finger. 
 
 
 
 
 
 
 
 
 
 
 
 67 
2.3 Subcellular localization of the non-regulatory protein CD147 
In the initial list of 101 proteins, there were a number of PM-resident proteins, whose ablation 
did not alter EGFR-NCE, that might represent cargoes of this internalization pathway. Among 
these, we analyzed in detail the matrix metalloproteinase inducer CD147/BSG. Considering 
the regulatory role of EGFR-NCE, we focused on CD147 known to be a tumor-associated 
antigen highly expressed on the surface of diverse tumors, analyzing in detail its subcellular 
localization and co-trafficking with the EGFR. 
To this aim, HeLa cells were stimulated with high dose of Alexa555-labelled EGF for 
2 and 8 minutes, fixed and stained for immunofluorescence (IF) analysis with anti-CD147 
antibody. We found that in non-stimulated cells, CD147 was mainly localized at the PM. 
Stimulation with EGF for 2 minutes, instead, resulted in the internalization and colocalization 
of EGF and CD147. The colocalization of EGF and CD147 was even more clear in cells 
stimulated for 8 minutes with EGF. These results indicate a possible co-trafficking of CD147 
with activated EGFR (Figure 22, upper panel). Note that a strong CD147 signal at the PM was 
present also upon EGF stimulation. CD147 internalization and colocalization with 
internalized EGF was scored also in clathrin KD cells (Figure 22, lower panel), suggesting 
that the co-trafficking may occur through NCE and that it may represent a good tool in the 
validation of this pathway.  
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Figure 22. CD147 internalization together with EGF.  
The localization of CD147 (green) in control or clathrin KD cells, in unstimulated or 
stimulated cells with Alexa555-EGF (red) for 2 or 8 minutes. DAPI (blue). Inserts highlight 
colocalization (yellow) between EGF and CD147. Scale bar, 10 μm. 
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2.4 Cross validation of NCE regulators and the CD147 cargo protein 
In order to further validate CD147 as a NCE cargo and, at the same time, to reinforce the role 
of the identified NCE regulators, we decided to test the impact of their ablation on CD147 
internalization. Given that the majority of CD147 remains at the PM and that only a small 
percentage of the protein is internalized upon EGF stimulation (see Figure 22), we set up a 
protocol to distinguish between PM CD147 and the internalized counterpart (45). In detail, to 
specifically follow the internalized CD147, we labeled cells in vivo with an antibody that 
recognizes the extracellular domain of the protein without interfering with its endocytosis 
(45), followed by stimulation with Alexa-conjugated EGF and fixation. To saturate the signal 
coming from CD147 at the PM, we proceeded with a first staining of the antibody at the PM 
without any permeabilization (Figure 23, magenta), after which we proceeded with a classical 
IF protocol, permeabilizing the cells and using a different secondary antibody for staining of 
CD147 (Figure 23, green). This second staining colors the internalized counterpart and the 
non-saturated CD147 at the PM.  
With this procedure, we confirmed the co-internalization of CD147 with EGF (Figure 
23), and found that the KD of all 9 identified regulators affected CD147 endocytosis, while 
EGF was still internalized, presumably through CME. Figure 23 shows representative data 
obtained from this analysis. Table 5 summarizes the quantitation of the inhibition of CD147 
internalization induced by the KD of each candidate. This analysis allowed us to cross 
validate the cargo and the regulators, and to demonstrate that CD147 represents a specific 
marker for NCE as ablation of the identified NCE regulators is able to impair its 
internalization upon EGF stimulation.  
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Figure 23. CD147 internalization.  
CD147 internalization was followed in control cells or in PLOD1 KD cells with a specific 
antibody. Cells were stimulated with high dose of Alexa555-EGF for 8 minutes (red). PM 
CD147 staining was performed before cell permeabilization (magenta, PM CD147). After cell 
permeabilization, staining of residual PM and intracellular CD147 (green, PM+intra CD147) 
was performed. Blue, DAPI. Scale bar, 10 μm.  
 
Table 5. The effect of NCE regulators on CD147 internalization.  
The percentage of cells in which CD147 internalization was blocked upon the KD of 
indicated genes is reported. At least 100 cells were counted in each condition. Dynamin 
(CME and NCE) and clathrin (CME only) are reported as controls. 
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3. RTN3 has a pivotal role in NCE 
Four out of nine NCE-functional regulators are ER proteins (see Table 4 and 5). We focused 
our efforts on analyzing reticulon 3 (RTN3), which showed one of the strongest phenotypes 
on EGFR and CD147 endocytosis (Table 4 and Table 5). RTN3 is an ER tubulation factor and 
belongs to the reticulon protein family (134). Interestingly, another reticulon family member, 
REEP5, that is involved in ER tubulation as well, is also present in our list of NCE regulators. 
 
3.1 RTN3 has specific effects on NCE 
3.1.1 RTN3 KD but not RTN4 KD blocks EGF and CD147 entrance trough NCE  
We performed 
125
I-EGF internalization assays to test the effect of RTN3 KD on EGFR-NCE. 
RTN3 KD reduced EGF internalization by ~50% at high dose of EGf (Figure 24a), which is 
compatible with the amount of EGFRs entering via NCE (22). The double KD of RTN3 and 
clathrin reduced EGF internalization almost to the same levels observed under conditions of 
dynamin KD (Figure 24a), demonstrating the requirement of RTN3 for EGFR-NCE. On the 
contrary, RTN3 KD showed only a minor impact on EGFR internalization at low EGF dose 
(Figure 24b) and no effect on Tf internalization, which is known to occur only via CME 
(Figure 24c).  
 We then assessed the effect of REEP5 KD on EGFR internalization and found that it 
reduces EGFR-NCE (Figure 24a). However, REEP5 KD is less efficient and less reproducible 
than RTN3 KD, thus we decided to start analyze the effect of RTN3 ablation on EGFR-NCE 
to obtain more reliable results. RTN3 and REEP5 form a complex with another reticulon, 
RTN4. The RTN3/REEP5/RTN4 complex has been implicated in cortical ER tubulation 
(135,136). Although RTN4 was not enriched in our MS screening, we decided to verify the 
effect of its KD on EGFR and CD147 NCE as a test of specificity. We found that RTN4 KD 
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did not affect EGFR internalization, neither at low nor at high dose of EGF (Figure 24a,b), 
arguing for a specific function of RTN3, and REEP5, in NCE. 
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Figure 24. The effect of RTN3, REEP5 and RTN4 on EGFR-NCE.  
a) and b) EGF internalization rate constants (Ke) at high (a) and low (b) dose of EGF in the 
indicated conditions.  
c) Ke of 
125
I-Tf internalization in the indicated conditions.  
d) Efficiency of RTN3 KD alone or in combination with the indicated genes was assessed by 
IB. The samples were loaded on two parallel gels (top and bottom). Dynamin 1 was blotted on 
the same membrane of dynamin 2 after stripping and re-blotting.  
e) Efficiency of RTN4 KD, REEP5 KD and clathrin KD was assessed by RT-qPCR. Residual 
mRNA expression in the KD samples was normalized using a housekeeping gene (GusB) and 
expressed as a fraction of the control. 
 
 
The strong and specific effect of RTN3 vs. RTN4 on NCE was confirmed by 
exploiting CD147 internalization. CD147 internalization was assessed in vivo as described in 
section 2.4 by stimulating the cells with Alexa555-EGF for 8 minutes. CD147 and EGF 
internalization proceeded in clathrin KD cells (see also Figure 22) but CD147 was blocked 
upon RTN3 KD, showing that RTN3 is indeed required for NCE (Figure 25a,b). The double 
KD of clathrin and RTN3 resulted in the inhibition of both CD147 and EGF endocytosis 
(Figure 25a), suggesting a comprehensive impairment of both CME and NCE.  
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Figure 25. RTN3 KD affects NCE.  
a) CD147 internalization was followed with a specific antibody in cells stimulated with high 
dose of Alexa555-EGF for 8 minutes (red) in the indicated conditions. PM CD147 staining 
was performed before cell permeabilization (magenta, PM CD147). After cell 
permeabilization, staining of residual PM and intracellular CD147 (intra) was performed 
(green, PM+intra CD147). Scale bar, 10 μm. Blue, DAPI.  
b) Quantification of CD147 internalization in the indicated conditions, expressed as 
percentage of cells in which CD147 is internalized compared to the control. 
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We then tested also the effect of RTN4 ablation on CD147-NCE. RTN4 KD did not show any 
impairment of CD147 internalization (Figure 26a,b), confirming that it does not play a 
functional role in NCE. These results reinforce the relevance and specificity of RTN3 
function in EGFR/CD147-NCE.   
 
Figure 26. RTN4 does not affect CD147 NCE.  
a) CD147 internalization was followed with a specific antibody in cells stimulated with high 
dose of Alexa555-EGF for 8 minutes (red) in control and RTN4 KD cells. PM CD147 
staining was performed before cell permeabilization (magenta, PM CD147). After cell 
permeabilization, staining of residual PM and intracellular CD147 (intra) was performed 
(green, PM+intra CD147). Scale bar, 10 μm. Blue, DAPI.  
b) Quantification of CD147 internalization in the indicated conditions, expressed as 
percentage of cells in which CD147 is internalized compared to the control. 
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3.1.2 Reintroduction of RTN3 restores EGFR and CD147 NCE 
In order to test if the effect of RTN3 ablation on NCE was specific and not due to an 
unspecific effect of the RNAi, we performed reconstitution experiments. There are seven 
isoforms described for RTN3 (Figure 27a). We initially evaluated if the RTN3 isoforms are 
expressed in our cell system (HeLa cells) by RT-QPCR analysis. We designed specific 
primers in order to discriminate between the different RTN3 isoforms and found that the most 
expressed isoform was isoform A (Figure 27b). Therefore, we decided to introduce a siRNA 
resistant form of RTN3A in our HeLa cells: we generated a cDNA of RTN3A that was 
resistant to the RNAi oligo used for RTN3 KD by introducing 8 silent mutations in the region 
targeted by the siRNA oligo by site-directed mutagenesis. The cells were then infected with 
pBABE-RTN3A siRNA-resistant and a clone expressing the transgene at endogenous levels 
was selected (Figure 28a). We then assessed that the exogenous expression of RTN3 was not 
affected by RTN3 siRNA oligo (Figure 28a). We evaluated the reconstitution of NCE upon 
RTN3 KD by RTN3A expression, both in 
125
I-EGF (Figure 28b) and CD147 internalization 
assays (Figure 28c). Results from both assays showed that the phenotype of EGFR and 
CD147 internalization was restored almost to wild-type (WT) levels by the reintroduction of 
RTN3A, indicating an almost complete rescue of the NCE pathway (Figure 28b,c). However, 
we cannot exclude that other isoforms may contribute to the NCE, possibly through 
oligomerization.  
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Figure 27. RTN3A isoforms.  
a) A schematic representation of the RTN3 gene and its 7 isoforms. Left, isoform name and 
accession number. The different exons are labeled with different colors and the corresponding 
number is indicated on the top. Oligos used in the qPCR analysis are indicated with arrows in 
different colors: green arrows indicate primers recognizing all isoforms except for isoform G; 
gray arrows indicate isoform-specific primers; red arrows indicate primers recognizing 
isoforms A, D and G.  
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b) Relative mRNA expression levels of the indicated isoforms were assessed by qPCR 
analysis. The normalization was performed using a housekeeping gene (GAPDH), expressed 
as relative to levels detected with primers recognizing all isoforms (except for isoform G).  
 
 
Figure 28. NCE restoration by exogenous RTN3A.  
a) RNAi resistant Isoform A of RTN3 was expressed in HeLa cells at endogenous levels. 
RTN3 endogenous and exogenous levels (indicated by arrows) were analyzed by IB in the 
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indicated conditions. Tubulin was used as loading control. This panel was assembled from 
samples run on the same gel.  
b) Internalization constants were measured by 
125
I-EGF internalization at high dose of ligand 
upon RTN3 KD or in control samples. Data are presented as the mean of duplicates of three 
independent experiments ± SD and are normalized to each control clone. *, P-value <0.05.  
c) CD147 internalization was followed in vivo as described in Figure 25 in the indicated 
conditions. Quantification of the percentage of CD147 internalizing cells in the different 
samples relative to control cells is indicated. Scale bar, 10 μm. Data are are presented as the 
mean of two independent experiments ± SD. 
 
3.2 RTN3 ablation affects EGFR degradation and increases its recycling 
We wanted to test the impact of RTN3 ablation also on the fate of internalized EGFR and 
analyzed the impact of RTN3 ablation on EGFR degradation. Considering that NCE destines 
the vast majority of internalized EGFR to degradation, impairment of the pathway should 
delay receptor degradation. We thus analyzed EGFR degradation in cells stimulated with high 
EGF doses (100 ng/ml) for increasing time points in order to follow EGFR degradation. Total 
EGFR levels were then detected by immunoblot (IB) analysis. In control cells, the receptor 
was almost completely degraded at 180 minutes post stimulation, while its degradation was 
delayed upon RTN3 KD (Figure 29a), thus confirming the role of RTN3 as a regulator of 
EGFR-NCE. These results were then confirmed in a more quantitative assay by following 
125
I-EGF degradation in cells stimulated with high dose of EGF. By measuring, at increasing 
time points, the ratio of degraded 
125
I-EGF compared with the total receptor, we observed a 
significant reduction in EGF degradation upon RTN3 KD (Figure 29b). 
 Based on these results, we hypothesize that the ablation of RTN3 may skew EGFR 
fate from a degradative to a recycling route.  We thus followed EGFR recycling using 
125
I-
EGF and found that stimulation of RTN3 KD cells with high dose of EGF resulted in an 
increased recycling of EGFR (Figure 29c), suggesting that, in these conditions, only the CME 
pathway, which is mainly devoted to receptor recycling, is active.  
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Figure 29. The effect of RTN3 ablation on EGFR degradation and recycling.  
a) Left, EGFR degradation (EGF, 100 ng/ml) was analyzed in control and RTN3 KD cells. 
Right, densitometric quantification, expressed as the percentage of EGFR levels relative to the 
initial amount.                                              
b) Quantitative 
125
I-EGF degradation assay. Data are expressed as percentage of degraded 
EGF. *, p <0.05 (vs. control).  
c) Quantitative 
125
I-EGF recycling assay. Data are expressed as percentage of recycled EGF. 
*, p <0.05 (vs. control). 
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4. Contact sites between the ER and the PM are involved in 
EGFR-NCE 
4.1 Identification of NCE intermediates  
In order to obtain information about the morphology of EGFR-NCE structures, we used high-
resolution electron microscopy (EM) technique in collaboration with Andrea Raimondi at the 
San Raffaele Institute, Milan.   
We employed pre-embedding immunolabeling for labeling of EGFRs in vivo with an 
antibody that does not interfere with receptor endocytosis (22) and marked it for EM with 
gold protein A. We then followed receptor internalization after stimulation with high dose of 
EGF for 5 minutes and we marked the structures that were still connected with the PM with 
Ruthenium Red (RuR). In control cells, gold-labeled EGFR was detectable both in clathrin-
coated pits (CCPs) and in tubular invaginations (TI, Figure 30a left). TIs persisted in clathrin 
KD cells (Figure 30a center), suggesting that they may represent the structures that mediate 
EGFR-NCE.  
We also assessed whether the formation of EGFR internalizing structures is affected 
by RTN3 KD, and found that upon RTN3 KD TI structures where significantly reduced in 
number, suggesting that these are indeed NCE intermediates and that their 
formation/stabilization is RTN3-dependent (Figure 30b); while RTN3 KD had no effect on 
CCPs (Figure 30c). 
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Figure 30. Characterization of EGFR-NCE by EM.  
a) Representative images of EGFR endocytic structures upon stimulation with high dose EGF 
in the indicated conditions. Scale bar 100 nm.  
b) and c) Quantification of gold-EGFR positive Tis and CCPs at 5 minutes of stimulation 
with high dose of EGF. Only RuR-stained structures were counted. N, number of cell profiles 
analyzed. Data are expressed as number of gold-positive structures normalized to PM profiles 
of 100 μm length. **, <0.01; ***, <0.001 (vs. control). 
 
4.2 RTN3 is an ER-localized protein 
To study the endogenous localization of RTN3, we produced a rabbit polyclonal antibody 
against amino acids (aa) 1-47, which are located in the N-terminal loop of RTN3 facing the 
cytosol (this region is common to all 7 RTN3 isoforms) and tested the specificity of its signal 
in IF analysis. We found that RTN3 showed the typical pattern of an ER protein and that the 
signal was significantly reduced upon RTN3 KD (Figure 31a). 
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To confirm the ER localization of RTN3, we tested the colocalization of endogenous 
RTN3 and the ER-resident protein Sec61β, expressed as a GFP-tagged chimera (Figure 31b 
top). We also co-transfected a tagged version of RTN3 together with the ER-localized protein 
ESYT1 (GFP-tagged) (137). We found that both RTN3 and ESYT1, showed a similar ER-
pattern as both proteins were enriched in cortical ER (Figure 31b bottom). We also tested the 
localization of RTN3 upon EGF stimulation but did not score any clear changes in RTN3 
localization by standard IF analysis except for a juxtaposition of cortical RTN3 signal and 
EGF (Figure 31b merge, enlargement).   
 
Figure 31. ER localization of RTN3.  
a) Characterization of the specificity of an anti-RTN3 antibody by IF analysis in HeLa control 
and RTN3 KD cells. Scale bar, 10 μm. Blue, DAPI.  
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b) Upper panel, colocalization, of endogenous RTN3 (red) and the ER-resident protein 
Sec61β-GFP (green) in HeLa cells stimulated with high dose Alexa647-EGF (magenta) for 2 
minutes. EGF Alexa647-EGF is shown as pseudocolored in grey (merge). Scale bar, 10 μm.  
b) Lower panel, colocalization of HA-RTN3 (red) and the ER-resident protein Esyt1-GFP 
(green) in HeLa cells stimulated with high dose Alexa647-EGF (magenta) for 2 minutes. EGF 
Alexa647-EGF is shown as pseudocolored in grey (merge). Scale bar, 10 μm. 
 
4.3 RTN3 and EGFR do not co-immunoprecipitate 
In order to investigate whether RTN3 is recruited in complex with the EGFR upon activation, 
we undertook co-immunoprecipitation (co-IP) studies. Clathrin KD cells were stimulated or 
not with high dose of EGF and subjected to IP analysis. In parallel, we also performed IP for 
RTN3, both in clathrin KD cells and in clathrin KD cells ablated also for RTN3 as a control 
for specificity. No co-IP was scored between EGFR and RTN3 in any of the conditions tested 
(Figure 32a,b). This data indicates that EGFR and RTN3 do not stably interact upon EGF. 
Considering that the interaction between RTN3 and EGFR could be indirect and/or transient, 
we decided to perform an image-based analysis, see section 4.4.  
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Figure 32. Immunoprecipitation of RTN3 and EGFR.  
a) Left, clathrin KD cells were stimulated for 2 minutes with high dose of EGF or left 
unstimulated in the indicated conditions and subjected to IP with a specific EGFR antibody 
(mouse). Right, controls of the IP efficiency were loaded and revealed with an EGFR 
antibody (rabbit).  
b) Left, clathrin KD cells were stimulated for 2 minutes with high dose of EGF or left 
unstimulated in the indicated conditions and subjected to IP with a RTN3 antibody (rabbit). 
Right, controls of the IP efficiency were loaded and revealed with a RTN3 antibody (rat). 
 
 
4.4 RTN3 is localized in close proximity to active EGFR 
4.4.1 Super resolution analysis to study signal clustering upon EGF stimulation 
To define the relationship between RTN3 and activated EGFR, we decided to employ super-
resolution microscopy and Förster resonance energy transfer (FRET) analysis due to the 
diffuse distribution of both RTN3 and EGFR. With the super-resolution microscopy technique 
it is possible to eliminate background signal coming from the presence of multiple 
fluorophores and to specifically localize the source of the signal. In particular, we took 
advantage of direct stochastic optical reconstruction microscopy (dStorm) (138) in 
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collaboration with Davide Mazza at the San Raffaele Institute, Milan. Cells were first 
incubated with an anti-EGFR antibody that does not alter its activation and endocytosis, and 
then stimulated with low or high dose of EGF for 2 minutes in order to follow the initial steps 
of endocytosis. Finally, cells were fixed and processed for IF by labeling EGFR with a 
secondary antibody (Cage550) that is specific for dStorm, and RTN3 with an Alexa-labeled 
(Alexa647) antibody that possesses the characteristics needed for this kind of microscopy (see 
Materials and Methods). The images of the channels of the two secondary antibodies were 
acquired and the list of detected molecules in the two channels was used to compute the cross-
correlation of the two images as described in (139) as follows: the cross-correlation curve was 
fitted by an exponential decay to quantify the degree of colocalization between EGFR-
Cage500 and RTN3-Alexa647 and the size of the co-clusters, respectively, provided by the 
cross-correlation amplitude C0 and the correlation length Rc. 
Upon EGF stimulation, we observed an increase in the proximity between the two 
signals (Figure 33a) quantified as co-clustering (C0) and cluster size (Rc). Only localization 
events occurring at the periphery of the cell were considered. This EGF-induced increase was 
significantly greater in cells stimulated with high dose of EGF compared to cells stimulated 
with low dose of EGF (Figure 33b). The two parameters were not measurable for serum-
starved cells. The increase in proximity induced by high EGF dose suggests that EGFR and 
RTN3 come into close proximity upon ligand stimulation. 
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Figure 33. EGF induced proximity between RTN3 and EGFR.  
a) dSTORM of RTN3 (green) and EGFR (red). Representative images of HeLa cells in the 
indicated conditions  (low EGF, 1 ng/ml; high 100 ng/ml). Scale bar, 0.7 μm.  
b) Left, cross-correlation between the two channels as a function of distance (139). No 
significant cross-correlation of the signal was observed in serum-starved conditions, 
indicating negligible co-clustering of the two proteins and implying that the size of the co-
clusters could not be estimated in these conditions. For EGF-induced samples, the cross-
correlation curves were fit to an exponential decay, providing (right): i) the amplitude of the 
correlation (C0) proportional to the fraction of co-clustered RTN3 and EGFR signals, and ii) 
the spatial extent of the cross-correlation curve (RC), which is an estimate of the size of the 
co-clusters. Stimulation of cells with high dose of EGF resulted in increased RC and C0 vs. 
low dose of EGF. 95% confidence intervals (CI) are presented in parenthesis. 
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4.4.2 Live FRET to study of EGFR-RTN3 proximity kinetic 
To kinetically follow the interaction between RTN3 and EGFR, prior and after EGF 
administration, we used live-FRET analysis, which allows the detection of transient/low 
affinity and indirect interactions with a resolution of 10-30 nm. To this aim, we transiently co-
transfected cells with EGFR-YFP/RTN3-CFP and measured the basal FRET level and 
followed its kinetics for 5 minutes of EGF stimulation. A significant increase in maximal 
FRET was registered upon cell stimulation with high dose of EGF, compared to basal 
conditions, (Figure 34b, red dots), suggesting that RTN3 and EGFR come into close 
proximity upon EGF stimulation. 
As controls, we also verified FRET of EGFR with different ER markers: STIM1 and 
RTN4 as markers e 
ER-localized construct CER17 (140) that labels all ER (Figure 34a). Interestingly, proteins 
enriched in cortical ER, like RTN3, gave a positive FRET signal within 5 minutes of EGF 
stimulation (Figure 34b, black dots), while proteins not enriched in the peripheral ER did not 
give a positive FRET signal (“all ER” markers, Figure 34b, grey dots). Representative images 
of the localization of the ER proteins and EGFR-YFP upon Alexa555-EGF stimulation of 
cells are shown in Figure 34a. 
In order to follow only FRET signal coming from activated EGFR, we restricted our 
analysis to the PM region by applying a mask based on Alexa555-EGF signal and followed 
the FRET signal for 3 minutes of EGF stimulation. We also discarded the signal coming from 
endosomes, excluding structures bigger then 0.2 µm
2
 (see Materials and Methods). We found 
that, among peripheral ER proteins, RTN3 was the one that gave the highest FRET signal in 
this specific setting (Figure 34c). All together, these results suggest that upon EGF 
stimulation, all cortical ER comes into close proximity with EGF-activated EGFR and that the 
first recruited protein is RTN3 (Figure 34b,c). 
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Figure 34. RTN3 proximity with EGFR is specific.  
a) Localization of the indicated CFP-tagged constructs or cerulean, and EGFR-YFP upon 
stimulation with Alexa555-EGF for 5 minutes. Scale bar, 10 μm.  
b) Sensitized Emission FRET analysis (SE-FRET). Normalized SE-FRET efficiencies of 
EGFR-EYFP in pair with the indicated ECFP-tagged constructs or cerulean-17, before (basal, 
left) and after stimulation with high dose of Alexa555-EGF for 5 minutes (high EGF, right). 
Red, RTN3; black, proteins enriched in cortical ER (“cortical ER”); grey, ER proteins not 
enriched in cortical ER (“all ER”). CER17, cerulean-1. **, P-value <0.01 (EGF-stimulated vs. 
basal condition).  
c) Measurement of close proximity at the PM. SE-FRET as in b) was restricted to regions 
where EGFR is activated at the PM by applying a mask based on Alexa555-EGF signal and 
following FRET for 3 minutes of EGF stimulation. 
 
 
4.5 ER contact sites with EGFR positive TIs are formed upon EGF 
stimulation and are RTN3-dependent.  
Our results obtained with super resolution and FRET were compatible with the proximity 
between activated EGFR at the PM and RTN3 in the ER through the formation of EGF-
induced ER-PM contact sites. To further explore this possibility, we took advantage of EM 
resolution. To better visualize the ER, HeLa cells were transiently transfected with HRP-
KDEL, a construct that is localized in the ER and that is visible as a black electrondense 
precipitate, leading to a clear visualization of the ER ((141,142) and Figure 35a). Cells were 
then labeled with anti-EGFR, as described in chapter 4.1, and stimulated with high dose of 
EGF. To test the presence of contact sites between activated EGFR and the ER, each EGFR-
positive structure (CCP or TI) was subjected to serial section analysis because gold-labeled 
EGFR and ER profiles were often not visible in the same section (Figure 35b for a scheme). 
We defined contact sites as those instances in which ER proximity (≤ 20 nm) to EGFR-gold-
positive PM invagination was present in at least one out of three sections (Figure 35c). We 
found that ~20% of EGFR-containing TIs were in contact with peripheral ER and observed 
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that no contact sites were present between ER and EGFR-containing CCPs (Figure 35d), 
suggesting that this might be a specific feature for EGFR-NCE.  
We then tested whether RTN3 is required for the formation of contact sites between 
the ER and EGFR-positive TIs. Serial section analysis showed that TIs that are retained in 
RTN3 KD cells had lost contact with the ER (only one out of 37 structures retained contact 
with the ER , Figure 35d). As control, we tested the effect of RTN4 KD on ER-TIs proximity 
but did not score any alterations in ER proximity with NCE structures (Figure 35e). These 
results show that RTN3 is required for the formation of specific contacts between the ER and 
sites of EGFR-NCE. RTN3-dependent contact sites are in turn required for TI 
formation/stabilization, as RTN3 KD inhibits their biogenesis. 
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Figure 35. ER-PM contact sites.  
a) HeLa cells were transfected with HRP-KDEL, visible as an electrondense precipitate, and 
stimulated with high dose of EGF (EGFR labeled with gold). Insets magnified on the right 
show the ER in contact with the PM (gold-labeled PM domains). Scale bar, left 1 µm, right 
200 nm.  
b) Cartoon depicting the rationale of serial sectioning. Arrows indicate ER-PM contacts.  
c) An example of serial sections showing contact sites (≤ 20 nm) between ER and gold-
EGFR-positive structures. Arrows indicate the same structures across the sections. Scale bar, 
100 nm.  
d) Mean frequency of ER proximity with gold EGFR-labeled CCPs or TIs expressed as 
percentage ± SEM. Absolute numbers above the bars indicate how many of the counted 
structures are in contact with the ER (distance ≤ 20 nm). Note that EGFR-positive CCPs were 
not found at ER contact sites. *, p <0.05 (vs. control TIs). 
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5. NCE PM-ER contacts are sites of local calcium release 
5.1 High dose of EGF induces a calcium wave at the inner leaflet of the PM 
ER contact sites are known to have a fundamental role in localized Ca
2+
 release (114) and 
high doses of EGF (10-100 ng/ml) are reported to induce a rapid increase in cytosolic Ca
2+
 
concentration (143,144). We, therefore, decided to assess whether this is the case for ER-PM 
contact sites involved in EGFR-NCE.  
In order to test if EGF is able to induce a Ca
2+ 
wave in correspondence with the PM, 
we exploited the calcium-activated photoprotein aequorin, isolated from the hydrozoan 
Aequorea victoria. In the presence of calcium, the protein undergoes a conformational change 
and, through oxidation, converts its prosthetic group, coelenterazine, into coelenteramide and 
CO2; blue light (wavelength of 465 nm) is emitted during this reaction and, once registered, 
can be converted into a calcium response. We compared the cytoplasmic version (cyto-
aequorin) with a version targeted to the inner leaflet of the PM by using aequorin fused with 
SNAP25, a neuronal protein that is recruited to the PM after the post-translational addition of 
a lipid anchor (PM-aequorin (145)). 
Cells were transiently transfected with aequorin and after probe reconstitution (see 
Materials and Methods), the calcium response was registered prior and after EGF addition. 
Aequorin detected a rapid peak of Ca
2+ 
induced by high dose of EGF (100 ng/ml). This peak 
was higher when detected with PM-aequorin compared to the cytoplasmic form, (Figure 36a, 
left), as also evidenced by measurement of the area under the curve (AUC, Figure 36a, right). 
This data suggests that the increase of [Ca
2+
] induced by EGF occurrs in proximity to the PM. 
The calcium wave was not detected at low EGF concentration (1 ng/ml, Figure 36b), 
indicating a correlation between EGFR-NCE activation and EGF-induced calcium release at 
the PM. 
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Figure 36.  Ca
2+
 wave induced by EGF.  
a) Left, measurements of [Ca
2+
] upon stimulation with high dose of EGF, using aequorin 
(cyto-Aeq, red curve) and a recombinant aequorin targeted at the PM inner leaflet (PM-Aeq, 
black curve). The corresponding area under the curve (AUC) in the two conditions is reported 
in the box plot on the right. *, P-value <0.05.  
b) Measurements of [Ca
2+
]PM, using PM-Aeq upon stimulation with high (100 ng/ml, black 
curve) or low (1 ng/ml, red curve) dose of EGF in control cells. The control curve is the same 
as in panel a). The corresponding AUC in the two conditions is reported in the box plot on the 
right. **, P-value < 0.01. 
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5.2 EGF-induced calcium flux does not depend on extracellular calcium 
The source of calcium flux in the cell could derive from intracellular stores or from 
extracellular space. To test whether the Ca
2+ 
flux induced by EGF was coming from the 
extracellular space, we sequestered extracellular Ca
2+
 with the Ca
2+
-chelator EGTA. Removal 
of extracellular calcium did not result in alteration of the EGF-induced peak intensity (Figure 
37, lower panel, right), but only minor effects on the decay phase of the curve were observed 
(Figure 37, upper panel and lower panel, left; see Discussion for possible explanations). This 
result shows that the EGF-induced Ca
2+ 
wave comes from intracellular compartments, 
possibly from the ER, which is the major storage compartment for intracellular Ca
2+
 (114). 
This result suggests that EGF induces a Ca
2+ 
release from the ER, possibly in correspondence 
with RTN3-dependent ER-PM contact sites. 
 
Figure 37. EGF-induced Ca
2+
 wave in the absence of extracellular calcium.   
Upper panel, measurements of [Ca
2+
]PM, using PM-aeq upon stimulation with high dose of 
EGF (100 ng/ml) in the presence or absence of extracellular calcium. Control cells where 
stimulated in saline buffer with calcium (black curve) or in saline buffer without calcium in 
the presence of the extracellular calcium chelator EGTA (red curve). The control curve is the 
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same as in the Figure 36a. The corresponding AUC in the two conditions is reported in the 
box plot on the right in the lower panel. **, P-value < 0.01. On the left, calcium peak values 
in the two conditions are reported. 
 
5.3 RTN3 KD affects EGF-induced calcium release 
Considering that RTN3 is required for the formation of contact sites between the ER and the 
PM (section 4.5), we wanted to test whether RTN3 ablation could have an effect also on the 
EGF-induced calcium wave observed with aequorin. We observed a strong reduction in Ca
2+ 
response upon stimulation with EGF in RTN3 KD cells (Figure 38a). We also tested the effect 
of RTN4 KD as a control and found that it had no effect on the EGF-induced calcium wave 
(Figure 38b). These findings corroborate the possibility that Ca
2+ 
is released upon EGF at ER-
PM contact sites and that these specifically depend on RTN3 function. 
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Figure 38. The effect of RTN3 KD and RTN4 KD on the EGF-induced Ca
2+
 wave.  
a) Measurements of [Ca
2+
]PM, using PM-aeq upon stimulation with high dose of EGF in 
control (black curve) and RTN3 KD cells (red curve). The corresponding AUC in the two 
conditions is reported in the box plot on the right. ***, P-value <0.001.   
b) Measurements of [Ca
2+
]PM, using PM-aeq upon stimulation with high dose of EGF in 
control (black curve) and RTN4 KD cells (red curve). The corresponding AUC in the two 
conditions is reported in the box plot on the right. 
 
5.4 Calcium is necessary for internalization of EGFR via NCE  
Once the dependence on RTN3 was defined also for the EGF-induced calcium wave, we 
wanted to test if the calcium movement induced upon stimulation with EGF was only a 
consequence or whether it is necessary for EGFR-NCE. We performed a calcium depletion 
procedure by combining EGTA and ionomycin treatment of the cells (146). The cells were 
kept in the presence of the calcium chelator EGTA and ionomycin to facilitate calcium exit 
from the ER to the extracellular space. After calcium depletion, intracellular calcium stores 
are emptied. We tested the effect of calcium depletion on endocytosis by stimulating the cells 
with Alexa555-EGF and assessing EGF and CD147 internalization. We observed that the 
internalization of CD147 was blocked, while the internalization of EGF was unaffected in 
cells treated with ionomycin. By combining ionomycin treatment with clathrin KD, both 
CD147 and EGF were blocked at the PM, suggesting that in these conditions both CME and 
NCE were blocked (Figure 39a) and that calcium depletion was sufficient to block the 
internalization of EGFR and CD147 through NCE. 
To verify the impairment of NCE upon intracellular calcium depletion, we performed 
125
I-EGF internalization assays. We found that ionomycin treatment does not alter EGF 
internalization at low dose of the ligand (Figure 39b, upper graph), while, at high dose of the 
ligand, the effect was comparable to that of RTN3 KD (Figure 39b lower graph), suggesting 
that calcium depletion, indeed, affects EGFR-NCE but not CME. The combination of 
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ionomycin treatment with clathrin KD at high dose of EGF reduced the internalization to 
levels comparable with those observed in cells depleted of both RTN3 and clathrin, 
confirming that intracellular Ca
2+
 is required for the internalization of EGFR via NCE (Figure 
39b). 
 99 
 
 100 
Figure 39. The effect of calcium on EGFR-NCE.  
a) CD147 (green) internalization was followed using a specific antibody in vivo as described 
in Figure 25, in control and clathrin KD cells, treated or not with EGTA and ionomycin and 
stimulated with high dose of Alexa555-EGF for 8 minutes (red). Scale bar, 10 μm.  
b) Internalization constants (Ke) were measured by 
125
I-EGF internalization at low (upper 
graph) and high (lower graph) doses of EGF in the indicated conditions. Mean of duplicates 
of a single experiment are shown.  
 
 
5.5 EGF-induced calcium release occurs through the activation of the IP3 
receptor on the ER 
5.5.1  Detection of EGF-induced calcium response at single cell level 
Considering the relative low sensitivity of aequorin, in parallel to the aequorin experiments, 
we validated some of the observed phenotypes with the ratiometric dye Fura-2 AM, a highly 
sensitive system that allows the evaluation of calcium response at single cell level. Note that, 
differently from aequorin, Fura-2, AM is more sensitive but measures the calcium movement 
in the cytosol and cannot be targeted to specific areas. Also in this case, we observed a 
calcium peak upon stimulation of cells with high dose of EGF, which was strongly affected 
by RTN3 KD but not by RTN4 KD (Figure 40a). Differently from PM-aequorin, we observed 
a calcium response also in cells stimulated with low dose of EGF, even if greatly reduced 
compared to the stimulation with high dose of EGF (Figure 40b, see Discussion for possible 
explanation).  
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Figure 40. Measurements of EGF induced calcium wave.  
a) Representative (single cell) cytosolic Ca
2+
 response induced by stimulation with high dose 
of EGF, in control (black curve), RTN3 KD (red curve) and RTN4 KD (green curve) cells 
loaded with Fura-2, AM. The kinetics of Ca
2+
 response is presented as the ratio of the 
fluorescence at 340/380 nm emission. The corresponding AUC in the different conditions is 
reported in the box plot on the right. ***, P-value <0.001.  
b) Representative (single cell) cytosolic Ca
2+
 response induced by stimulation with high dose 
of EGF, (black curve) or low dose of EGF (blue curve) of cells loaded with Fura-2, AM. The 
kinetics of Ca
2+
 response is presented as the ratio of the fluorescence at 340/380 nm emission. 
The control curve is the same as in panel a). The corresponding AUC in the different 
conditions is reported in the box plot on the right. ***, P-value <0.001. 
 
 
5.5.2 IP3R inhibition affects EGF-induced calcium wave and NCE progression 
The activation of the ER receptor inositol-3-phosphate (IP3R) is the main pathway that 
promotes Ca
2+
 release from the ER in HeLa cells (147). In order to test if this pathway is 
implicated in the calcium wave observed upon EGF stimulation, we tested the effect of 
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xestospongin C, a selective IP3R inhibitor, on the EGF-induced calcium wave by using Fura-
2 AM. We observed that xestospongin C treatment strongly affected EGF-induced Ca
2+
 flux 
to an extent comparable to RTN3 KD (Figure 41), suggesting that the EGF-induced calcium 
release occurs through the opening of IP3Rs on the ER membrane. 
 
Figure 41. The effect of xestospongin on the EGF-induced calcium wave.  
Top, representative (single cell) cytosolic Ca
2+
 response induced by stimulation with high 
dose of EGF, in control (black curve), xestospongin C-treated (Xesto, dotted black curve), 
RTN3 KD (red curve) and xestospongin C-treated RTN3 KD (dotted red curve) cells loaded 
with Fura-2, AM. The kinetics of Ca
2+
 response is presented as the ratio of the fluorescence at 
340/380 nm emission. The corresponding AUC in the different conditions is reported in the 
box plot at the bottom. ***, P-value <0.001. 
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 Considering that EGFR-NCE requires both ER-PM contact sites and calcium release 
from the ER to the PM, we wanted to define if the calcium release is required for contact site 
formation or if it is an event that occurs after their establishment. To study the timing of these 
events, we tested if the blockage of IP3R-dependent calcium release induced by EGF could 
alter the formation of ER-PM contact sites in EGFR-NCE. Since the proximity between 
RTN3 and EGFR can be assessed by FRET analysis (see Figure 34), we tested if 
xestospongin C treatment could lead to an alteration of this proximity induced by EGF using 
this method. We did not observe any alterations in the proximity between EGFR and RTN3 
upon xestospongin treatment (Figure 42). These data suggest that Ca
2+
 release by IP3R is 
downstream of ER-PM contact site formation. 
 
Figure 42. Xestospongin treatment does not alter EGFR-RTN3 proximity.  
Sensitized Emission FRET analysis (SE-FRET). The figure shows the normalized SE-FRET 
efficiencies of EGFR-EYFP in pair with the RTN3-ECFP, before (basal) and after stimulation 
with high dose of Alexa555-EGF for 5 minutes (EGF) in cells treated (red dots) or not (white 
dots) with xestospongin C. ***, P-value <0.001 (EGF-stimulated vs. basal condition). 
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 Finally, we tested whether the calcium needed for NCE progression was the one 
released from IP3R by assessing EGFR and CD147 internalization after xestospongin C 
treatment. We found that xestospongin C is able to impair CD147 internalization, indicating 
that it inhibits NCE. When we combined xestospongin C treatment with clathrin KD to block 
both NCE and CME, we observed an inhibition of both EGF and CD147 internalization 
(Figure 43). Overall, these results are compatible with the possibility that high doses of EGF 
induce a calcium wave through the opening of IP3R at ER-PM contact sites, which is in turn 
required for NCE to proceed.  
 
Figure 43.  The effect of xestospongin C on NCE internalization.  
CD147 (green) internalization was followed using a specific antibody in vivo, as described in 
Figure 5, in control cells, treated or not with xestospongin C (Xesto), and in xestospongin C-
treated clathrin KD cell, stimulated with high dose of Alexa555-EGF for 8 minutes (red). 
Scale bar, 10 μm. Blue, DAPI. Right, percentage of cells in which CD147 is internalized in 
the different samples is indicated.  
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6. A new probe to study calcium release at the PM 
We wanted to increase the “resolution” in the study of the EGF-induced calcium wave and to 
use a probe targetable at the inner leaflet of the PM, as aequorin, but that gives information at 
single cell level, as Fura-2, AM. To do so, we tested the chimeric protein GCaMP6f, that for 
its relative low affinity for calcium is also ideal for the evaluation of calcium potentials 
closely spaced in time (148). We used both the cytosolic version of this probe and a version 
fused with SNAP25 (see section 5.1 for aequorin). First, we evaluated the PM staining of the 
SNAP25 version and we confirmed that the presence of the protein at the PM did not alter 
EGF internalization upon stimulation of cells with Alexa555-EGF (Figure 44a). We found 
that the internalization of EGF was not altered by GCaMP6f transfection. Then, we compared 
the cytosolic and the PM version of the probe. We did not observe any significant calcium 
response upon EGF stimulation with the cyto-GCaMP6f. The PM-GCaMP6f probe, instead, 
showed an oscillatory calcium response with pronounced and repetitive calcium peaks (Figure 
44b, black curve). This data highlights an interesting calcium response in quanta that we were 
not able to observe with PM-aequorin.  
This preliminary data supports our previously observed phenotype; the reduced 
calcium response upon RTN3 KD and xestospongin C treatment (Figure 44b, red and green 
curves); thus confirming that the calcium release induced by EGF is occurring through IP3R 
specifically in correspondence with the PM. 
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Figure 44. EGF-induced calcium wave detected by PM-GCaMP6f.   
a) HeLa cells were transfected with the PM-GCaMP6f construct (SNAP25 fusion) and 
stimulated with Alexa555-EGF.  
b) Top, representative (single cell) Ca
2+
 response at the PM induced by stimulation with high 
dose of EGF in control (black curve), RTN3 KD (red curve) and xestospongin C-treated 
(Xesto, green curve) cells transfected with PM-GCaMP6f. The kinetics of Ca
2+
 response is 
presented as the ratio of fluorescence at 490/406 nm emission. The corresponding AUC in the 
different conditions is reported in the box plot at the bottom. *, P-value <0.05. 
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DISCUSSION 
 
1. The uniqueness of EGFR-NCE 
We have characterized a new clathrin-independent endocytic pathway, responsible for the 
internalization of the EGFR and triggered by stimulation with high dose of EGF. The 
uniqueness of this pathway relies on the fact that it is functionally distinct from all other NCE 
pathways described so far in the literature (8,27,42,45,48,50,52,53,149-151). Indeed, our 
extensive analysis, performing KD of players known to be involved in other clathrin-
independent endocytic routes and evaluating their effect on EGFR-NCE, did not identify any 
player that is specific only for NCE: we either scored no effect or a more general effect on 
endocytosis. This is the case for the actin-regulators Cdc42 and Rac, which appear to alter not 
only NCE, but also CME and the constitutive pathway, suggesting that their effect can be due 
to a general alteration of the actin machinery affecting the structure of the cell. 
With the scope to identify key molecular players specifically involved in EGFR-NCE, 
we developed a protocol to isolate and molecularly characterize EGFR-NCE vesicles. This 
analysis was followed by an extensive validation procedure and led us to the identification of 
a number of regulators that have not been implicated in endocytic routes but are specifically 
involved in EGFR-NCE. We dissected the pathway by following EGFR internalization and 
found an additional PM cargo, CD147, with no active role in EGFR-NCE, but that, upon EGF 
stimulation, exploits the same route as EGFR for its internalization.  
The great novelty of the EGFR-NCE pathway relies on the finding that it requires the 
establishment of contact sites between the ER and the PM for its execution, a feature that until 
now has not been addressed for any endocytic pathway. However, the width of the impact of 
EGFR-NCE in different cellular contexts, and if this pathway always relies on the same 
mechanism of internalization, is an issue that remains to be addressed. 
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We have previously shown that a clathrin-independent, dynamin-dependent pathway 
for the EGFR, which is activated at high EGF concentrations, is not restricted to our model 
system, HeLa cells, but can be observed in different cell lines, although its existence is clearly 
cell context dependent (111). When this analysis was performed, we did not have molecular 
tools, like RTN3 as a functional regulator or CD147 as a marker of NCE, to investigate the 
system. Therefore, we are currently screening different cell lines again, using these more 
specific tools to define the presence of EGFR-NCE in other model systems. This analysis will 
clarify if EGFR-NCE relies on the same molecular mechanism and players in different 
cellular contexts. Moreover, we plan to widen the analysis to test if other receptors, 
particularly other RTKs, exploit the same endocytic route. 
 
2. ER resident proteins regulate EGFR-NCE  
Among the identified EGFR-NCE players, four are proteins resident in the ER (RTN3, 
REEP5, PLOD1, P4HB); RTN3 and REEP5 showed one of the strongest and more specific 
effects on EGFR-NCE upon ablation. RTN3 is an ER membrane-associated protein of the 
reticulon family and REEP5 is closely related. Four RTN genes have been identified in 
mammals: RTN1, RTN2, RTN3 and RTN4. The RTN proteins have been found to be 
primarily associated with the ER, where they act as shaping factors, and in some cases a small 
fraction has been found present also at the level of the PM (136,152). 
Reticulon proteins contain a Reticulon Homology Domain (RHD) at the C-terminus, 
formed by two hydrophobic patches flanking a hydrophilic loop. There are different 
hypotheses regarding the topology of the RHD region, this segment can span the membrane 
or double back on itself to form a hairpin (Figure 45).  
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Adapted from Yang and Strittmatter, Genome Biology, 2007 (134) 
Figure 45. Possible topologies of reticulon proteins.  
Several topologies have been hypothesized for reticulon proteins but only the three topologies 
depicted in the figure have been verified. 
 
 
Considering several evidences supporting diverse possible RTN structures, the best 
explanation is that, in mammals, reticulon proteins can adopt different conformations, 
conferring to this protein the ability to carry out multiple roles inside the cell (134). This 
diversity is present also at the gene level, for example, RTN3 has seven different isoforms 
(see Results Figure 27) and whether these can have a different localization, function or tissue 
expression is still unknown. Differently from RTN3, REEP5 has only one single isoform but 
possess the RHD region and possibly adopts the same structure as RTN3. Importantly, it has 
been demonstrated that RTN3 and REEP proteins oligomerize at the level of the ER, and that 
this interaction is required for tubulation of cortical ER (136). 
Considering the hairpin-like topology, reticulon structure could resemble the structure 
of caveolins and flotillins at the PM (Figure 46). Like caveolins and flotillins at the level of 
the PM, RTN3 and REEP5 can induce membrane curvature and generate tubules at the level 
of peripheral ER membranes (136). In particular, our data suggest that RTN3 might exert its 
function in EGFR-NCE from an ER location, without any translocation at the level of the PM, 
supported by the fact that we could not detect any RTN3 at the PM. However, we cannot 
exclude that a minor fraction of RTN3 might have escaped our detection. 
Extracellular space
ER lumen
Cytoplasm
CC C
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Adapted from Bauer and Pelkmans, FEBS Letters, 2006(153) 
Figure 46. Putative membrane topologies of membrane-coat proteins and reticulons. 
Membrane topologies of caveolin-1 a), RTN4c/NogoC b) and Reggie-1/Flotillin-2 c) are 
depicted. All three proteins possess a hydrophobic sequence that does not cross the 
membrane. Putative phosphorylation sites are also represented. 
 
 
It would be interesting to evaluate the specific function of the other two ER-associated 
proteins PLOD1 and P4HB. PLOD1 (Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase 1) 
is an ER membrane-bound lysyl hydroxylase and catalyzes the hydroxylation of lysyl residues 
in collagen-like peptides, a modification that is critical for the stability of mature collagen. 
P4HB (the beta subunit of prolyl 4-hydroxylase) is a disulfide isomerase that, among other 
functions, is involved in the hydroxylation of prolyl residues in preprocollagen, in the 
regulation of disulfide bonds, and in the control of misfolded proteins. Since these two 
proteins are enzymes, it would be interesting to study if their function is specifically required 
for EGFR-NCE.   
 
 
 
c) b) a) 
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3. ER-PM contact sites are required for EGFR-NCE  
We used RTN3 as a molecular tool to characterize EGFR-NCE since it has all the 
characteristics of a specific regulator of this pathway. In particular, we observed that the 
RTN3 KD blocks EGFR internalization through NCE and leads to a complete inhibition of 
EGF internalization when combined with clathrin KD at high EGF dose. Moreover, the KD of 
RTN3 delayed EGFR degradation, leading to an increase in its recycling - as expected under 
conditions of EGFR-NCE inhibition, which preferentially devotes receptors to degradation 
into lysosomes (63). Furthermore, RTN3 ablation blocked the internalization of the cargo 
protein CD147 through NCE. 
  One issue that arises from our purification procedure is why we recovered ER-
resident proteins associated with NCE vesicles. This is reminiscent of the so-called 
"mitochondria-associated ER membranes" (MAMs). Indeed, MAMs were initially considered 
"contaminants" of the mitochondrial fractions (154,155), but successive studies defined 
MAMs as ER structures in close contact with mitochondria (156). Similarly, our 
morphological studies by EM suggest an extensive association of the ER with sites of EGFR-
NCE that may be responsible for the recovery of the ER fraction in our vesicle purification. 
These contacts seem to be a peculiarity of NCE; indeed, we could not identify any contact 
sites between the ER and EGFR-containing CCPs.  
There are multiple evidences of contact sites between the ER and endocytic 
organelles, as well as with the PM in the literature. A direct role for contact sites in the 
internalization step has, however, never been described (117,121,157,158). Given that the ER 
is one of the main calcium and lipid reservoirs in the cell, it is not surprising that ER contact 
sites with the PM are requested for phosphoinositides and calcium signaling, and for lipid 
transport (90,141,159,160). Considering the great mobility of the ER to precisely locate 
enzymes and proteins with a specific function, contact sites can have a role also at endocytic 
sorting stations where they can establish a functional crosstalk between different 
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compartments without fusion of the two (119,121,161,162). An example of this crosstalk 
between ER and endosomes is the regulation of EGFR fate by the action in trans of the ER-
phosphatase PTP1B on the internalized receptor localized at the endosomal level (125). 
Importantly, ER-contact sites also have a more active role as they are, together with dynamin 
and actin, involved in the regulation of fission events of endosomes or mitochondria 
(117,123). Interestingly, EGFR-NCE requires dynamin and we have evidence that show that 
also actin is required in this process (preliminary data, not shown). Thus, we could speculate 
that the cell may use the same molecular machinery for different functions, which, like in this 
case, may be related. The involvement of ER in membrane fission might be not only at the 
level of mitochondria and endosomes, as already reported, but also at the level of the PM in 
correspondence with EGFR-NCE sites.  
 
 
4. What is the role of RTN3 in EGFR-NCE contact site formation 
and stabilization? 
RTN3 is necessary for the formation of ER contact sites with EGFR-positive PM structures 
and for the maturation of TIs, which represent the NCE intermediates. Moreover, we showed 
that ER-localized RTN3 is recruited in close proximity to active EGFR, specifically upon 
EGF stimulation (Figure 34). Considering the great mobility and flexibility of the ER, we can 
hypothesize that the tubulating function of RTN3 is necessary for the function of ER in 
EGFR-NCE. The strongest evidence in support of this hypothesis is the fact that RTN3 is 
required for the formation of ER-PM contact sites induced by EGF. In favor of this idea, 
another ER tubulation factor, REEP5, has a similar function. The two proteins, RTN3 and 
REEP5, are reported to be able to form a complex (136). Moreover, we can envision 
specificity in the system, since another member of the reticulon family, RTN4, also involved 
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in the tubulation of the ER, apparently does not have an active role in NCE. One hypothesis 
could be that specific regions (or domains) of the ER can be under the control of dedicated 
factors to execute precise functions. Thus, RTN3 and REEP5 might represent prototypes of 
such "dedicated" tubulation factors. At present, however, we cannot exclude that the function 
of RTN3 might depend on activities other than ER tubulation. 
Another hypothesis is that RTN3 acts as a tethering factor between the ER and the PM 
after EGFR activation by the ligand. In support of this hypothesis, we observed close 
proximity between RTN3 and activated EGFR, and specific FRET signal between the RTN3-
EGFR pair specifically upon EGF treatment. Other cortical ER proteins showed FRET with 
EGFR after EGF stimulation; however, analyzing the FRET signal in correspondence with the 
PM and during the first minutes of stimulation, thus excluding EGF-positive endosomes, we 
found that RTN3 was the only protein under scrutiny that gave a strong FRET signal. We 
failed, however, to detect co-immunoprecipitation between the EGFR and RTN3. We can 
speculate that a putative RTN3-EGFR association is labile or stoichiometrically below 
detection limits; another possibility is that a protein bound to RTN3 acts as a tethering factor 
or that RTN3 interacts with a PM protein that is close to the EGFR. 
 
 
5. The role of ER-PM contacts in NCE: TI maturation and local 
Ca
2+
 release  
ER-PM contacts appear to be required for EGFR-NCE at the level of TI formation and 
maturation. One possibility is that the ER may work as an anchor for TI stabilization, which 
otherwise are instable and do not mature. Although we cannot exclude a structural role for 
ER-contact sites in EGFR-NCE, our data shows that they could have a functional role, 
working as platforms for EGF-induced local Ca
2+
 release from the ER at a location close to 
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the PM, which is, in turn, required for the completion of the internalization process. These 
findings integrate well with previous knowledge that ER-PM contacts are sites of localized 
calcium signaling (114) and with the fact that stimulation with high dose of EGF induces an 
intracellular calcium wave (143,144). However, this is the first evidence that EGF-induced 
calcium release occurs at ER-PM contact sites and that it is directly involved in EGFR 
internalization. We showed that the massive calcium wave is triggered only upon stimulation 
with high dose of EGF. This is critical since EGFR-NCE is also activated only at high EGF 
concentrations. We have previously shown that EGFR ubiquitination, which is required for 
EGFR-NCE, has a similar behavior (68). The two systems may be related in their regulation 
and we can speculate that the existence of multiple controls on EGFR-NCE activation is 
needed to ensure the activation of the pathway only at high doses of the ligand.  
We have also dissected the signaling cascade, showing that stimulation with high dose 
of EGF is required to activate the IP3R on the ER, leading to Ca
2+
 release from this organelle 
to the PM. Our data indicate that this calcium release is needed to complete the internalization 
process: blocking the IP3R calcium release with the drug xestospongin, as well as ER-calcium 
deprivation, impairs EGFR-NCE. Importantly, the calcium release is downstream the RTN3-
depedent formation of contact sites since blocking calcium release from the ER did not affect 
the proximity between active EGFR and RTN3. Thus, our data suggest a positive feedback 
loop that links EGFR-NCE and Ca
2+
 signaling: high dose of EGF triggers ER-PM contact site 
formation and NCE activation, which induces local Ca
2+
 release at contact sites and, in turn, 
the Ca
2+
 flux is required to finalize EGFR-NCE.  
Upon EGF-induced release of calcium, the ER needs to reload it, and we can 
hypothesize that this operation may include the induction of store-operated-calcium-entry 
(SOCE). In the ER, the transmembrane protein STIM1 acts as a calcium sensor; when 
calcium is released from the ER is also detached from STIM1, inducing conformational 
changes that lead to the relocalization of STIM1 to ER sites near the PM where it can 
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associate with Orai1 to induce SOCE. These events lead to the entrance of calcium into the 
cytoplasm, sustaining the calcium elevation. Calcium is then re-acquired into the ER thanks to 
the action of sarco/ER Ca
2+
-ATPase (SERCA) (163). We can, thus, hypothesize that this 
system of calcium re-acquirement by the ER is present also after the calcium release induced 
by EGF. Indeed, when we analyzed the EGF-induced calcium wave in the presence of EGTA, 
an extracellular calcium chelator, we did not observe any effect on the EGF-induced calcium 
peak; however, we scored an effect on the second phase of the curve (Figure 37, Results), 
which decayed more abruptly, likely due to the lack of activation of SOCE as a consequence 
of the extracellular calcium depletion. The activation of SOCE, however, should represent a 
secondary effect due to the emptying of ER-calcium, and should not have a direct role in 
EGFR-NCE. Indeed, our preliminary data shows that STIM1 KD does not affect EGFR-NCE. 
Further investigations will be needed to reinforce this possibility. Interestingly, another 
reticulon, RTN4, has been linked to ER tubulation-dependent calcium regulation. In 
particular, upon RTN4 KD, the ER changes its morphology profoundly, moving from tubules 
to ER sheets, and the blocked ER tubulation appears to be sufficient to impair the coupling 
between STIM1-Orai1, representing the first demonstration of a role of RTNs in calcium 
signaling (164). 
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Adapted from Chen, Journal of Biomedical Science, 2013 (165) 
Figure 47. STIM1 regulation of SOCE.  
(1-2) Depletion of ER Ca
2+
 causes Ca
2+
 dissociation from STIM1 and STIM1 
oligomerization. (3) STIM1 relocalization at ER-PM sites. (4-5) Orai1 goes from an inactive 
state to the formation of the active STIM1/Orai1 complex that opens the Orai1 channel, 
allowing Ca
2+
 entry. (6) Upon ER refilling, STIM1 binds calcium again. 
 
 
STIM1-Orai1 interactions are not the only ER-PM contacts regulated by calcium. 
Indeed, the elevation of cytosolic calcium induced by SOCE triggers the recruitment of E-
Syt1 (Extendend Synaptotagmin-1), a transmembrane protein resident in peripheral ER 
(137,141), at the PM. The formation of these tightly regulated contact sites can be required to 
facilitate lipid exchanges between the ER and the PM. Moreover, other members of the E-Syt 
family (E-Syt2 and E-Syt-3) that are not regulated by calcium, are also involved in contact 
site formation but rely on the interactions of E-Syt proteins with PI(4,5)P2 at the level of the 
PM (141). Interestingly, we found E-syt1 in our MS screening but its ablation, alone or in 
combination with the KD of E-syt2 and E-syt3, did not alter EGFR-NCE. These results 
suggest, once again, specificity in contact site and calcium-regulated pathways.  
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6. A possible role for calcium in EGFR-NCE 
The mechanism of Ca
2+
 action is not known. In the literature, there are evidences for the 
involvement of calcium in endocytic events at the synapse (166). The problem with the 
analysis of calcium at synapses is that it is difficult to separate the study on endocytosis from 
the exocytic process of neurotransmitter release, a process regulated by calcium (166). 
Moreover, data on the effect of calcium in the endocytic process at synapses are discordant; 
indeed, calcium has been shown to be able to have a positive, a negative or no effect on 
endocytosis (167). It is possible that calcium signaling can have different outputs depending 
on the cell line under scrutiny or that calcium is differentially required in distinct endocytic 
pathways (168). Calcium has an established role in CME at synapses; it is able to regulate the 
interaction between dynamin 1 and calcineurin that act as a calcium sensor. Calcineurin is 
activated when it binds calcium and then dephosphorylates different proteins belonging to the 
synaptic endocytic machinery, among which dynamin 1, that upon dephosphorylation can 
localize at the PM and regulate endocytosis (169,170). Given this direct role of calcium in the 
activation of dynamin 1 in neurons, one possibility could be that in EGFR-NCE the EGF-
induced calcium may be required for the regulation of dynamin 2 function, although no 
evidence for this is present in the literature.  
Another hypothesis is that calcium may be critical for rearrangements of the actin 
cortex cytoskeleton that is required to facilitate the fission of endocytic intermediates from the 
PM. Indeed, actin appears to be required in different NCE pathways for the fission step, in 
some cases together with dynamin (4,5,32,49,52). Moreover, many enzymes involved in the 
actin machinery appear to be regulated by calcium, first of all gelsolin, which is needed for 
actin polymerization, and also the actin-binding proteins myosin II and L-plastin. Other 
proteins are not directly regulated by calcium but are controlled by the calcium-dependent 
protease calpain. Among these proteins, there are talin, ezrin and WASp (Wiskott-Aldrich 
syndrome); the latter, in particular, is involved in the activation of the Arp2/3 complex that is 
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required for the polymerization of new F-actin. Close correlation between calcium signaling 
and actin remodeling has been described especially in T-cell activation. In this cell context, 
polymerization of actin appears to be necessary for the calcium release upon activation of the 
T-cell receptor (TCR) and, in a bidirectional control, calcium is needed for cytoskeletal 
remodeling (171). Actin is important in the control of the calcium cascade also because it is 
involved in the formation of the scaffold that is necessary for the association of the TCR with 
the enzyme PLCγ (172).  
PLCγ plays an important role in the calcium cascade, from the scission of 
phosphatidylinositol 4,5-bisphosphate PLCγ produces IP3 and diacylglycerol (DAG). In 
EGFR-NCE, IP3 is necessary for the release of calcium from the ER and is known that PLCγ 
is directly phosphorylated and activated by the EGFR (173). We are currently evaluating the 
role of PLCγ in EGFR-NCE, by analyzing phosphorylation of PLCγ in response to increasing 
EGF doses, and the impact of PLCγ inhibition on the EGF-induced Ca2+ wave and EGFR 
internalization. Together, these experiments will help us define the molecular cascade that 
leads to the release of Ca
2+
 from the ER upon stimulation with high EGF doses. We are also 
planning to test if the alteration of PLCγ could have any impact on actin and, conversely, if 
the alteration of the actin machinery would result in an altered regulation of PLCγ.   
 
7. Classical and new techniques to follow calcium signaling 
We undertook two techniques to follow calcium kinetics: aequorin and Fura-2, AM. Aequorin 
can be targeted at the PM, where NCE-contact sites take place, and gives information about a 
population of cells; however, it has a relatively low sensitivity for calcium and requires a 
good level of transfection. On the other side, Fura-2, AM is a diffusible probe that does not 
need any transfection and does not provide information about the localization of the calcium 
wave, but , instead, is more sensitive compared to aequorin and provides information about 
the calcium kinetics at a single cell level. Considering the lower sensitivity of aequorin, it was 
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important for us to characterize all phenotypes observed with PM-aequorin also with Fura-2, 
AM. This double approach led us, for example, to conclude that a calcium movement cannot 
be excluded upon stimulation of cells with low dose of EGF (Figure 36b and Figure 40b). 
Thus suggesting that EGF is able to induce a calcium wave also at low dose, in this case, 
however, the release occurs more likely in the cytosol and not specifically at the PM since we 
were not able to score a clear calcium response with PM-aeq in cells stimulated with low dose 
of EGF.  
Currently, we are characterizing a new, interesting calcium-probe, GCaMP6f (174) 
that can be targeted in different cellular compartments, like aequorin, but has higher calcium 
sensitivity compared to aequorin. GCaMPs have been developed for imaging of calcium 
peaks in neurons (165), in which calcium levels change rapidly and, thus, require an adequate 
probe with an accelerated off-response, broad sensitivity range of calcium and a good signal-
to-noise ratio. Importantly, GCaMP6f appears to be a good tool also to follow calcium 
response in the context of EGFR-NCE: we confirmed the phenotypes scored with the other 
techniques and, in addition, this probe is able to detect the typical oscillatory behavior of 
calcium peaks that are not easily visible with aequorin or Fura-2, AM. We scored the 
formation of repeated peaks of calcium at the PM that we can describe as “quanta” that may 
be associated with specific “quanta” of signaling in cells stimulated with high dose of EGF. 
Further experiments are needed to unravel this fascinating possibility. 
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8. NCE cargoes  
We identified CD147 as a cargo that can enter the cell together with EGFR through NCE 
upon EGF stimulation. Importantly, differently from EGFR, CD147 is internalized almost 
exclusively via NCE in this specific setting and can, thus, be used as a specific marker for 
NCE. Of note, the entrance of CD147 into NCE structures is unlikely to be a passive 
entrapment, since CD147 internalized only into EGFR-containing TIs and not into EGFR-
internalizing CCPs (unpublished data). Thus, the mechanism induced by EGF stimulation 
might regulate its entrance specifically via NCE. For EGFR, we have shown that 
ubiquitination is the signal that activates NCE (22,111).  Intriguingly, CD147 was previously 
found in the EGF-regulated Ubiproteome (175). In addition, in the literature, growing 
evidences indicate that trafficking of PM transporters and carriers, among which also CD147, 
is regulated by ubiquitination (46,176,177). Thus, we can speculate that CD147 
internalization through NCE depends on EGFR-activated ubiquitination events. This scenario 
might be true for other PM proteins subjected to regulation by ubiquitination. 
CD147 is a transmembrane glycoprotein particularly enriched in PM of tumour cells 
and correlates significantly with poor prognosis in breast and ovarian cancer (178,179). 
CD147 has different functions but is primarily involved in the induction of matrix metallo-
proteinases, a feature that renders CD147 responsible for different malignant features like 
invasiveness and anchorage-independent growth (180). Thus, regulation of CD147 PM levels 
and its intracellular fate by EGFR-NCE could be relevant for tumor progression and invasion.   
Additional connections between MMP-9 (metallo-proteinases 9), one of the principal 
MMPs induced by CD147, calcium and EGF are present in the literature. In particular, it has 
been proven that calcium and EGF act together in wound healing, being more effective 
together than alone (181). Furthermore, in the absence of MMP-9, EGF alone does not o 
stimulate migration, but the increase of calcium concentration reverts this phenotype (181), 
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suggesting an interesting correlation between EGF, calcium and MMP9, one of the main 
substrates controlled by the NCE-cargo CD147. 
 
9. Different players and integration of their function in EGFR-
NCE 
It remains to be established whether the identified candidates are involved in EGFR-NCE. 
The mechanisms underlying this pathway appear relatively complex, as the list of regulators 
includes, apart from ER, also mitochondrial, nuclear and RNA-binding proteins.  
One of the most interesting candidates is Enoyl CoA hydratase 1 (ECHS1). The 
enzyme ECHS1 catalyzes the second step of mitochondrial fatty acid beta-oxidation by 
hydration of enoyl CoA intermediates to the S-hydroxyacyl-thioesters. ECHS1 works as a 
homohexamer with an integrated hydratase activity and, in fractionation studies, was found 
associated with mitochondrial membranes (182). Considering the function of ECHS1, and the 
fact that EGFR-NCE relies on cholesterol/sphingolipids-enriched PM microdomains (lipid-
rafts); an interesting hypothesis is that ECHS1 might regulate lipid rafts at the level of the 
PM, influencing EGFR-NCE. It is possible that a small percentage of the enzyme is localized 
or translocated at the PM, or ECHS1 may act from its mitochondrial localization in 
correspondence with mitochondria-PM contact sites (183). 
Functional crosstalk between PM, ER and mitochondria has been reported; for 
example, it is known that calcium coming from the extracellular space first has to cross the 
ER and can then be directed into mitochondria (184). Moreover, PM-ER-mitochondrial 
association has been proposed to regulate SOCE (183,185). Considering these evidences, the 
presence of mitochondria in correspondence with ER-PM contact sites might be connected to 
local calcium fluxes needed for EGFR-NCE. To test this hypothesis, we will perform 
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localization studies using EM analysis in order to visualize possible contact sites between 
mitochondria and PM in correspondence with EGFR-NCE structures.  
In the literature, a possible role for RNA-binding proteins in different cell functions is 
emerging, for example in cell signaling (186), cell spreading (187), cell adhesion and 
migration (188). In EGFR-NCE, RNA-binding proteins might be involved in local translation 
of proteins (e.g., NCE functional regulators) at sites where they act, as reported for actin 
(188), or may recruit RNAs (e.g., non-coding RNAs, ncRNAs) that have a structural role, 
acting as molecular scaffold or signaling platforms, as it was shown in DNA damage response 
(189,190) and in the regulation of transcription (191). An interesting link between signaling 
from tyrosine-kinase receptors and RNA can be represented by one of the functional 
regulators, KHDRBS1, also known as Sam68. This protein is tyrosine phosphorylated and it 
can interact with SH2-containing proteins; it was shown to interact with the SH3 domain of 
Grb2 and to bind to RNA; thus, it can possibly work as a docking station to recruit other 
signaling molecules (192). Sam68 if often found in complex with up to 40 proteins, many of 
which are RNA-binding proteins and, interestingly, some evidences suggest that, upon EGF 
stimulation, Sam68 exits from these complexes and localizes into smaller ones. This 
translocation appears to be linked with the ability of Sam68 to promote cell migration upon 
stimulus (193). 
To conclude, we have described a novel modality of internalization that depends on 
the formation of ER-PM contact sites and possibly requires the integration of numerous 
cellular functions. Further studies will define if the functional regulators identified in this 
study are involved only in EGFR-NCE or if they are also involved in other endocytic 
pathways. NCE has a major role in the regulation of EGFR as it is involved in the regulation 
of receptor degradation. It is now important to characterize the possible alterations of NCE 
players in pathological conditions involving aberrant receptor signaling. 
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10. Future directions 
10.1 EM analysis to unravel the role of NCE-functional regulators 
We have extensively characterized the effect of RTN3 KD on NCE function and morphology, 
especially through the usage of EM. We plan to extend this analysis to other NCE regulators 
in TI formation and in contact site formation by using ruthenium red and HRP-KDEL 
staining, respectively. These experiments will allow us to understand whether other NCE 
regulators are acting upstream or downstream of RTN3. In particular, we will first 
characterize the remaining three ER-resident proteins (REEP5, PLOD1, P4HB) identified in 
our proteomic screening, which could have a role in the formation of ER-PM contact sites. 
We will then characterize the role of ECHS1, due to its mitochondrial localization, and 
considering the known association between mitochondria, ER and PM (114), it will be 
interesting to evaluate the effect of ECHS1 KD on NCE structures and even on the 
localization of mitochondria. 
 
10.2 The interaction of ER proteins with EGFR  
Based on the hypothetical, indirect interaction between EGFR and RTN3, we aim to identify 
other ER-resident proteins that may directly contact the active EGFR at the PM and work as 
tethering factors. To this aim, we plan to employ unbiased proteomics strategies, such as the 
APEX2 technique, that has been already successfully employed for ER-PM junction 
proteomics analysis (194). In order to enrich for ER-localized or ER-proximal proteins, we 
will exploit an APEX2 construct targeted at the level of the ER membrane. We will stimulate 
cells with high dose of EGF to induce the formation of ER-PM contact sites in 
correspondence with activated EGFR. Thanks to the activity of APEX2, proteins that are in 
close proximity with the ER will be biotinylated upon addition of biotin-phenol and will be 
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easily recovered by IP with beads covered with streptavidin, allowing for isolation of protein 
in close proximity and/or transiently interacting with EGFR. We will couple this IP with an IP 
against EGFR in order to specifically select what is both EGFR-bound and biotinylated. Thus, 
we will recover proteins involved in the formation of ER-PM contacts that are required for the 
NCE of EGFR. 
 
10.3 Defining the role of RTN3 and other NCE players in EGFR signaling, 
degradation and biological responses 
Our laboratory has previously showed that NCE plays a crucial role in EGFR 
downmodulation and signal extinction (63). We have already tested the effect of RTN3 
silencing on EGFR degradation by WB and 
125
I-EGF-based degradation assays in HeLa cells. 
Importantly, we scored a significant delay in EGFR degradation upon RTN3 KD. We now 
wish to extend the analysis of the effect of RTN3 KD on EGFR internalization to other cell 
lines in order to identify a suitable cell model, in addition to HeLa cells, to study the impact of 
NCE on EGFR signaling outputs. We will then assess the effects of RTN3 silencing on i) 
EGFR signaling, by assessing the activation of the EGFR (e.g., EGFR phosphorylation and 
ubiquitination) and downstream effectors (e.g., Shc, ERKs, PI3K,) by WB analysis; ii) EGF-
dependent calcium signaling; and iii) EGF-dependent biological responses, such as 
proliferation (growth curves, colony assays in 2D-culture and in 3D-semisolid medium, i.e., 
soft agar assay) and/or migration (wound healing, transwell assay).  
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10.4 Defining the relevance of EGFR-NCE in physiology and cancer 
Given the role of EGFR-NCE in signal extinction in the presence of high ligand 
concentration, an intriguing hypothesis is that alterations of NCE might contribute to aberrant 
EGFR signaling in cancer. We will screen a panel of human normal vs. cancer primary cells 
(lung, prostate and/or breast, available at our Institute through a collaboration with the 
Molecular Medicine Unit at the IEO, Milan) by performing 
125
I-EGF internalization assays 
upon KD of clathrin (CME is inhibited), RTN3 (NCE is inhibited), or dynamin (CME and 
NCE are inhibited) to verify the existence of the NCE pathway in primary cells and its 
possible alteration in cancer cells. Depending on the results, analysis of EGFR 
degradation/signaling and EGF-dependent proliferation will be performed. 
Moreover, in order to characterize possible alterations of RTN3, as the best-
characterized NCE functional regulator, we plan to analyze RNA samples coming from 
different types of cancer. We will analyze the presence of RTN3 mutations, its splicing 
patterns and the levels of RTN3 expression; eventually, this analysis will be extended to other 
NCE regulators. We will first focus on breast and lung cancer, for which we have enormous 
collections of patient material and complete clinical follow-up data. 
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MATERIALS AND METHODS 
 
1. Solutions 
1.1   Phosphate-buffered saline  
NaCl 137 mM 
KCl 2.7 mM 
Na2HPO4 10 mM 
KH2PO4 2 mM 
 
8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4, and 0.24 g of KH2PO4 are solved in 800 ml of 
distilled H2O (ddH2O). The pH is adjusted to 7.4 with HCl and volume is brought to 1 litre 
with ddH2O. 
 
1.2   Tris-HCl (1 M) 
121.1 g of Tris base are dissolved in 800 ml distilled H2O. The pH is adjusted to 7.4, 7.6 or 
8.0 (depending on the case) with HCl, and ddH2O is added to bring volume to 1 litre. 
 
1.3   Tris-buffered saline (TBS) 
NaCl 137 mM 
KCl 2.7 mM 
Tris HCl pH 7.4 25 mM 
 
8 g of NaCl, 0.2 g of KCl, and 3 g of Tris base are solved in 800 ml of distilled H2O. 
The pH is adjusted to 7.4 with HCl and ddH2O is added to bring volume to 1 litre. 
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1.4   10X SDS-PAGE running buffer 
Glycine 192 mM 
Tris HCl, pH 8.3 250 mM 
SDS 1% 
 
1.5   10X Western transfer buffer 
Glycine 192 mM 
Tris HCl, pH 8.3 250 mM 
For 1X western transfer buffer, the 10X stock is diluted 1:10 with ddH2O and 20% v/v 
methanol or ethanol is added. 
 
1.6 10X Tris EDTA  
Tris HCl, pH 7.4 100 mM 
EDTA, pH 8 10 mM 
 
1.7 50X TAE (Tris-Acetate-EDTA)  
Tris base 2 M 
Acetic acid 1 M 
EDTA, pH 8 10 mM 
The pH is adjusted to 8.5 with HCl and ddH2O is added to 1 litre. 
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2. Protein buffers 
2.1 1X JS buffer 
HEPES, pH 7.4 50 mM 
NaCl 150 mM 
Glycerol 10% 
Triton X-100 1% 
MgCl2 1.5 mM 
EGTA 5 mM 
 
200X Proteases inhibitor cocktail from Calbiochem, sodium pyrophosphate pH 7.5 20 mM, 
sodium fluoride 250 mM, PMSF 2 mM, and sodium orthovanadate 10 mM are added to the 
buffer just before use. 
 
2.2 1X Laemmli buffer 
SDS 2% 
Tris HCl, pH 6.8 62.5 mM 
Glycerol 10 % 
Bromophenol blue 0.1 % 
-Mercaptoethanol  5 % (v/v)  
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3. Reagents   
EGF was from PeproTech; Alexa-EGF (555 and 647) were from Molecular Probes; 
125
I-EGF 
and 
125
I-Tf from PerkinElmer. Protein-A Gold 10 nm was from Utrecht University; EM grade 
glutaraldehyde and paraformaldehyde employed for EM were from Electron Microscopy 
Sciences; ruthenium red is from Sigma. Fura-2, AM was from ThermoFisher. Ionomycin, 
calcium chloride, Pluronic F-68, sulfinpyrazone, coelentarazine were from Sigma. 
Xestospongin C was from Abcam. 
 
3.1   Antibodies 
Primary antibodies were: rabbit polyclonal anti-EGFR (in-house), directed against amino 
acids 1172-1186 of human EGFR, used in IB; mouse anti-EGFR 13A9 (Genentech) used to 
follow endocytosis in EM analyses and in super-resolution; mouse anti-CD147 (BD); rabbit 
and rat anti-RTN3 (in-house), directed against amino acids 1-47, common to all isoforms; 
anti-dynamin-1, anti-dynamin-2, (Santa Cruz); anti-HA (BABCO); anti-tubulin (Sigma); anti-
clathrin heavy chain used for IB (BD). Fluorescent secondary antibodies were from Molecular 
Probes. Cage 550 secondary antibody for Super-resolution microscopy was from Aberrior. 
 
3.2   RNAi oligos 
Silencing oligo sequences were: 
clathrin heavy chain (Riboxx): UAAAUUUCCGGGCAAAGAGCCCCC 
dynamin 1 (Riboxx): UUUCACAAUGGUCUCAAAGCCCCC 
dynamin 2 (Riboxx): UGAACUGCAGGAUCAUGUCCCCC 
Caveolin-1 (Dharmacon): GGCCAGCUUCACCACCUUC 
Cdc42 (Stealth, Invitrogen): CCUCUACUAUUGAGAAACUUGCCAA 
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GRAF1 (Stealth Select RNAi™ siRNA): CCACUCAUGAUGUACCAGUUUCAAA 
Rac1 (Stealth, Invitrogen): CCGGUGAAUCUGGGCUUAUGGGAUA 
Rac2 (Stealth, Invitrogen): ACCUGCCUUCUCAUCAGCUACACCA 
Arf6 (Stealth, Invitrogen): AAGCTGCACCGCATTATCAATTT 
RhoA (Stealth, Invitrogen): GAUACCGAUGUUAUACUGAUGUGUU 
RTN3-2 (Stealth, Invitrogen): 5'-CCCUGAAACUCAUUAUUCGUCUCUU-3' 
REEP5-4 (Riboxx): UUAAUUGAGAUGUAGGCUGCCCCC 
For RTN4 KD, we used two silencing oligos (Stealth, Invitrogen):  
RTN4-1: 5’-CCAGCCUAUUCCUGCUGCUUUCAUU-3’   
RTN4-2: 5'-CCUAUUCCUGCUGCUUUCAUUGACA-3' 
For Endophilin A1 and A2 KD, we used a single silencing oligo and a pool of four oligos 
(Riboxx), respectively: 
Endophilin A1: 5'-AUUAUUUCCAUCACAGCCCCC-3' 
Endophlin A2-pool: 5'-UUUGAAGUCAUCAUCCAGCCCCC-3' 
5'-UCUUCUUGUAGUCAAAGUCCCCC-3' 
5'-ACUGGAACCUUUGUGCUUGCCCCC-3' 
5'-UCGAUCCCAUCCUGUUAAGCCCCC-3' 
For ZFR KD, we used a pool of four oligos (Riboxx): 
ZFR_1 UUUAUUUCCUGUUGACUGCCCCC 
ZFR_2 AUAUGAGUAUGAAUCCUGGCCCCC 
ZFR_3 ACUUUAGUGUUAGAUGUGCCCCC 
ZFR_4 AUAAUACCUAACACUGUACCCCC 
For ECHS1 KD, we used a pool of four oligos (Riboxx): 
ECHS1_1 AUUCACUGAUUCUUUGGCCCCC 
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ECHS1_2 UAUCACUUUAAUCAGCAUCCCCC 
ECHS1_3 UUCCUAUUAAGAUCUCCGGCCCCC 
ECHS1_4 ACUUCCUUCUGUUAAUGUCCCCC 
For P4HB KD, we used a pool of four oligos (Dharmacon): 
P4HB_1 CCAAGAGUGUGUCUGACUA 
P4HB_2 GUGACGUGUUCUCCAAAUA 
P4HB_3 GAACGCACGCUGGAUGGUU 
P4HB_4 UGACAUACCAUUUGGGAUC 
For PLOD1 KD, we used a pool of four oligos (Dharmacon): 
PLOD1_1 CUGGACGACUCACGCAUUA 
PLOD1_2 GAGAACGUGCCGACUAUUG 
PLOD1_3 AGAGGGAGCAGAUCAAUAU 
PLOD1_4 CUUCGUCGAUCCCUAAUUG 
For LRPPRC KD, we used a pool of four oligos (Dharmacon): 
LRPPRC_1 UAACAUAGAUGCCGCAAUA 
LRPPRC_2 GAUGAGAGAUGCCGGAAUU 
LRPPRC_3 GAAAUUAGGUGCUGUGUAU 
LRPPRC_4 GUACAAGGAUGGACGUUAU 
For TPR KD, we used a single oligo (Dharmacon) 
TPR_1             GAAGAAGUGCGUAAGAAUA 
For KHDRBS1 KD, we used a single oligo (Dharmacon) 
KHDRBS1_1   GAAAGAGCGAGUGCUGAUA 
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3.3   TaqMAN assays for Q-PCR (ThermoFisher) 
Gene Symbol TaqmMAN assay 
SH3GL1 Hs04235263_g1 
SH3GL2 Hs00182352_m1 
RTN4 Hs01103689_m1 
REEP5 Hs01075582_m1 
CLTC Hs00964480_m1 
 
 
4. Cloning technique 
 
4.1 Agarose gel electrophoresis 
DNA samples were loaded on 0.8%-2% agarose gels along with DNA markers. Gels were 
made in TAE buffer containing Gel Red (Biotium), according to manufacturer instructions, 
and run at 80 V until desired separation was achieved. DNA bands were visualized under a 
UV lamp. 
 
4.2 Minipreps 
Clones picked from individual colonies were used to inoculate 2 ml LB (containing the 
appropriate antibiotic) and grown overnight at 37°C. Bacteria were transferred to Eppendorf 
tubes and pelleted for 5 minutes at 16,000 xg. Minipreps were performed with the Wizard 
Plus SV Minipreps Kit (Promega) following manufacturer instructions. The plasmids were 
eluted in 50 μl nuclease free H2O. 
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4.3 Diagnostic DNA restriction 
Between 0.5 and 5 μg DNA were digested for 2 hours at 37°C with 10-20 units of restriction 
enzyme (New England Biolabs). For digestion, the volume was made up depending on the 
DNA volume to 20-50 μl with the appropriate buffer and ddH2O. 
4.4 Large scale plasmid preparation 
Cells containing transfected DNA were expanded into 250 ml cultures overnight. Plasmid 
DNA was isolated from these cells using the Qiagen Maxi-prep kit according to manufacturer 
instructions. 
 
4.5 Transformation of competent cells 
An aliquot of competent cells TOP10 (Invitrogen) were thawed on ice for approximately 10 
minutes prior to the addition of plasmid DNA. Cells were incubated with DNA on ice for 30 
minutes and then subjected to a heat shock for 45 seconds at 42°C. Cells were returned to ice 
for 5 additional minutes. Then, 300 μl of SOC was added and the cells were left at 37°C for 
further 60 minutes before plating them onto plates with the appropriate antibiotic. Two plates 
for each reaction were used, one plated with 100 μl of the transformed bacterial cells and the 
other one with the rest. Plates were incubated overnight at 37°C. 
 
5. Constructs and plasmids  
Human RTN3A cDNA (NM_006054) was purchased from Origene (pCMV6-AC-GFP 
vector) and cloned by PCR in the pECFP-N1 vector (Clontech) or in the pBABE-puro vector  
fused to HA-tag (22). Human EGFR was subcloned from pBABE-EGFR (111), (22) in 
pEYFP-N1 vector (Clontech). Esyt1-GFP was a kind gift from Pietro De Camilli (Yale 
School of Medicine). Cerulean-17 (Cer-17) was a kind gift from Nica Borgese (CNR, Milan). 
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Cerulean empty vector was a gift from Dave Piston (Addgene plasmid #15214). RTN4a-GFP 
was a kind gift from Gia Voeltz (Addgene plasmid #61807), pAc-GFPC1-Sec61β was a gift 
from Tom Rapoport (Addgene plasmid #15108), STIM1-CFP was a gift from Anjana Rao 
(Addgene plasmid # 19755). RTN4a and STIM1 were subcloned by PCR in pECFP-N1 
vector (Clontech). Sec61β was subcloned by PCR in pCDNA3-ECFP vector (Addgene), 
generating ECFP-Sec61β. Snap25-Aequorin was a kind gift from Pinton Lab (195).pGP-
CMV-GCaMP6f was a gift from Douglas Kim (Addgene plasmid # 40755) and for the 
SNAP25 tagged version the sequence of Snap25-Aequorin was used as template for the PCR 
reaction.  
All clones were sequence-verified.  
The primers were designed of similar length and annealing temperature (calculated running 
the primers on simulated PCR reactions, using MacVector programme). The primers were 
designed with suitable restriction sites, or according to the manufacturer instruction when 
used the In-Fusion HD® PCR cloning. These primers were used in a PCR reaction together 
with the DNA template and the Phusion high fidelity DNA polymerase (FINNZYMES), 
according to manufacturer instructions. Primers are listed in the following table: 
RTN3A_XhoI_F GGCGCTAGCATGGCGGAGCCGTCGGCG 
RTN3A _ XhoI_R GGCGCTAGCGCTTCTGCCTTTTTTTTGGCG 
EGFR_ XhoI _F CGCTCGAGATGCGACCCTCCGGGACG 
EGFR _ SacII_R CGCCGCGGTGCTCCAATAAATTCACTGC  
Sec61β_EcoRI_F GCTGTACAAGGAATTCCCTGGTCCGACCCCCAGT 
Sec61β_EcoRI_R GATATCTGCAGAATTCCTACGAACGAGTGTACTTG 
RTN4a_BamHI_F CGCGGGCCCGGGATCATGGAAGACCTGGACCAG 
RTN4a_BamHI _R GGCGACCGGTGGATCTTCAGCTTTGCGCTTCAATC  
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Stim1_BamHI_F CGCGGGCCCGGGATCATGGATGTATGCGTCCGTC 
Stim1_BamHI _R GGCGACCGGTGGATCCTTCTTAAGAGGCTTCTTAAA 
Snap25_BglII_F TACCGGACTCAGATCTATGGCCGAAGACGCAGAC 
Snap25_BglII_R CATGGTGGCGAGATCTATACCACTTCCCAGCATCT 
The cycling parameters are summarized in the following table. 
Step Temperature Time # Cycles 
A 98°C 30 seconds 1 
B 98°C 
50-65°C (calculated for each primer pair) 
72°C 
30 seconds 
30 seconds 
60 seconds 
 
25-30 
C 72°C 7 minutes 1 
D 4°C ∞ 1 
 
5.1 Site directed mutagenesis 
For rescue experiments, we generated a cDNA of RTN3A resistant to RNAi oligo RTN3-2 
(section 3.2) by introducing 8 silent mutations by site-directed mutagenesis (oligo seq: 
GTTGATCATCCGCTTGTT) into the pBABE-HA-RTN3A construct. 
 
6. Cell culture 
6.1   Cell culture media 
HeLa cells were grown in GlutaMAX™-Minimum Essential Medium (MEM, Gibco 
Invitrogen), supplemented with 10% FBS (PAA), sodium pyruvate 1 mM (Euroclone), non-
essential aminoacids (Euroclone).  
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6.2   Transfections 
- RNAi transfections 
RNAi transfections were performed using LipofectAMINE RNAi MAX reagent from 
Invitrogen. Cells were treated according to the following scheme: 
Day 1 Reverse transfection 250,000 cells in a 6-well plate 
8 nM RNAi oligo 
4 μl of LipofectAMINE RNAi MAX 
Day 2 Forward transfection 8 nM RNAi oligo 
4 μl of LipofectAMINE RNAi MAX 
Day 3  -  
Day 4 Split cells  Cells plated at the proper concentration 
for the final assay 
Day 5 Check KD 
Assay 
 
 
 
- DNA transfection with FuGENE 
For immunofluorescence study, DNA transfections were performed using FuGENE 6 reagent 
from Roche, according to manufacturer instructions. Briefly, cells were plated at 50% 
confluency on gelatin-coated coverslips placed in 10-cm dishes. The day after cells were 
transfected with 8 μg DNA and 6 μl FuGENE 6. 24 hours after transfection cells were 
stimulated with Alexa555-EGF and internalization assay was performed.  
- DNA transfection with calcium phosphate 
For aequorin and GCaMP6f measurements, cells were plated on 13mm coverslips placed in 6 
wells plates in order to obtain for the day after cells at 40-60% of confluence. After 24 hours 
from plating, cells were transfected with the mix obtained adding to 100 μl of HBS solution 
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(50 mM HEPES, 280 mM NaCl, 1.5 mM Na2HPO4, pH to 7.0), the mix composed by 10 μl 
of CaCl2, 6 μg of DNA to a volume of 100 μl with sterile H2O. The reaction was left for 20 
minutes at RT to allow the formation of complexes and was then added drop by drop on cells 
and left over night at 37 
o
C. The day after cells were washed with PBS at least four times to 
remove the precipitate and fresh medium was added. 48 hours post transfection cells were 
analyzed. 
 
6.3   Retroviral infection 
Stable population of HeLa cells expressing RTN3A (used for reconstitution experiments) 
were generated by infecting cells with retroviral vector. Retroviruses were produced by 
transfecting the Phoenix helper cell line with 5 μg of DNA. 48 hours after transfection, 
supernatant was collected and passed through  a 0.45 μm filter. After the addition of 8 μg/ml 
polybrene (Hexadimethirne bromide, Sigma), the supernatant was added to HeLa cells plated 
on 10 cm cell culture dishes. Two cycles of infection were repeated, after which the medium 
was replaced by standard HeLa medium. 48 hours after infection, selection of infected cells 
was performed by adding puromycin at a concentration of 1.5 μg/ml. 
 
7. Protein procedures 
7.1 Cell lysis  
After washing with PBS 1X, cells were lysed in JS directly on the plates using a cell-scraper 
and clarified by centrifugation at 16,000 xg for 10 min at 4ºC. Protein concentration was 
measured by the Bradford assay (Biorad), following manufacturer instructions. 
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7.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Gels for resolution of proteins were made from a 30%, 37,5:1 mix of acrylamide: 
bisacrylamide (Sigma). As polymerisation catalysts, 10% ammonium persulphate (APS) and 
TEMED were used. 
Separating gel mix 
 Gel % 
 6 8 10 15 
Acrylamide mix (ml) 2 2.7 3.3 5 
1.5M Tris HCl pH 8.8 (ml) 2.5 2.5 2.5 2.5 
ddH2O (ml) 5.3 4.6 4 2.3 
10% SDS (ml) 0.1 0.1 0.1 0.1 
10% APS (ml) 0.1 0.1 0.1 0.1 
TEMED 0.01 0.01 0.01 0.01 
TOTAL (ml) 10 10 10 10 
 
Stacking gel mix 
Acrylamide mix (ml) 1.68 
1M Tris HCl pH 6.8 (ml) 1.36 
ddH2O (ml) 6.8 
10% SDS (ml) 0.1 
10% APS (ml) 0.1 
TEMED (ml)  0.01 
TOTAL (ml)  10 
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7.3 Western Blot (WB) 
Desired amounts of proteins were loaded onto 1.5 mm thick SDS-PAGE gels for 
electrophoresis (Biorad). Proteins were transferred in western transfer tanks (Biorad) to 
nitrocellulose (Schleicher and Schnell) in 1X Western transfer buffer (supplemented with 
20% methanol) at 30 V overnight or 100 V for 1 hour.  
Otherwise proteins were loaded onto Criterion™ TGX™ gels (Biorad) and trasferred with 
Trans-Blot® Turbo™ Nitrocellulose with the Trans-Blot® Turbo™ Transfer System 
(Biorad). 
Ponceau staining was used to reveal roughly the amount of protein transferred to the filters. 
Filters were blocked 1 hour (or overnight) in 5% milk in TBS supplemented with 0.1% Tween 
(TBS-T). After blocking, filters were incubated with the primary antibody, diluted in TBS-T 
5% milk for one hour at room temperature, followed by three washes of five minutes each in 
TBS-T and then incubated with the appropriate horseradish peroxidase-conjugated secondary 
antibody diluted in TBS-T for 30 min. After the incubation with the secondary antibody, the 
filter was washed three times in TBS-T and the bound secondary antibody was revealed using 
the ECL method (Amersham). 
 
7.4   Co-Immunoprecipitation 
Lysates prepared in JS buffer were incubated in the presence of specific antibodies (about 1-2 
μg/mg of lysates) for 2 hours at 4ºC with rocking. Protein G Sepharose beads (Zymed) were 
then added, and samples were left for an additional hour at 4ºC, rocking. Immunoprecipitates 
were then washed 4 times in JS buffer.  
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8.   Quantitative real-time PCR analysis  
Total RNA was extracted from HeLa cells (control and KDs, as indicated) using the RNeasy 
kit from Qiagen, according to the manufacturer’s protocol. Single stranded cDNA synthesis 
was performed using the QuantiTect Reverse Transcription Kit (Qiagen) following 
manufacturer’s instructions.  
For the analysis of RTN3 isoform expression in HeLa cells, the QuantiFast SYBR Green PCR 
Kit (Qiagen) was used, according to manufacturer’s instructions. Light cycler 480 instrument 
for qPCR was from Roche.  
Below is the sequence of the oligos used: 
RTN3(A+D+G)-for   5'-CTGTGCGGTGCACGATCT-3’ 
RTN3(A+D+G)-rev  5'-ACAGCTTGGATGACGGACTT-3’ 
RTN3B-for    5'-CTGTGCGGAGGGATTGAG-3’ 
RTN3B-rev   5'-GCTCCCTAACACATGGCTTT-3’ 
RTN3C-for    5'-ACCTCACAAGTGCACGATCT-3’ 
RTN3C-rev   5'-TGACAGAGAGAAGAGCCAGGA-3’ 
RTN3D-for    5'-TGAGAAGTACAAGGATCCAAGC-3’ 
RTN3D-rev   5'-AATGGTGTTTTAGTAACTGTTGCATT-3’ 
RTN3E-for    5'-CCTCACAAGAGGGATTGAGC-3’ 
RTN3E-rev   5'-TAGGCTGGCTCCCTAACACA-3’ 
RTN3F-for    5'-CTGTGCGGCCAGTTTCCC-3’ 
RTN3F-rev   5'-CTCAGTAGGTGGTTTCTGGGCTG-3’ 
RTN3G-for    5'-CCATTCAAACCCAGATTGATC-3’ 
RTN3E-rev*   5'-AATGGTGTTTTAGTAACTGTTGCATT-3’  
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(*same as RTN3D-rev) 
RTN3all(-G)-for 5'-ACAGCCAGCTTCAAGGAGTC-3’ 
RTN3all(-G)-rev 5'-TGGAAAGCTTCTGAGGACAG-3’ 
 
 For the analysis of KD levels by RT-qPCR, the Taqman chemistry (Thermo Fisher 
Scientific) was used. qPCR instrument was from Applied Biosystems. For the different genes, 
inventoried Taqman assays (Applied Biosystems) were employed. 
 
9. Assays with 
125
I-EGF and 
125
I-Tf 
9.1 Internalization assay with 
125
I-EGF and 
125
I-Tf 
Cells were serum starved for at least 2 hours and then incubated at 37°C in the presence of 
125
I-EGF or 
125
I-Tf in binding buffer (MEM, BSA 0.1%, Hepes pH 7.4 20 mM). The 
concentration of radiolabelled EGF/Tf used in the assays was the following: 
 
LOW DOSE EGF internalization 
125
I-EGF: 1 ng/ml 
HIGH DOSE EGF internalization 
125
I-EGF: 1 ng/ml                                     
+ unlabelled EGF: 29 ng/ml 
Tf internalization 
125
I-Tf: 1 ng/ml 
 
After the indicated time points (2, 4, 6 min), cells were put on ice, washed three times in PBS, 
and then were incubated for 5 minutes at 4°C in 300 l of acid wash solution pH 2.5 (acetic 
acid 0.2 M, NaCl 0.5 M). Then, the solution was removed from the cells and the radioactivity 
present into it was measured. This sample represents the amount of 
125
I-EGF/Tf bound to the 
receptor on the cell surface. Cells were then lysed with 300 l of a solution containing 1M 
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NaOH. This sample represents the amount of internalized 
125
I-EGF/Tf. The unspecific 
binding was measured at each time points in the presence of an excess of non-radioactive 
EGF/Tf  (300X and 500x respectively). After being corrected for non-specific binding, the 
rate of internalization was expressed as the ratio between internalized and surface-bound 
radioactivity. Endocytic rate constants [Ke and Ke obs, (111) were calculated from the slope 
of the trend-line. Results are expressed as the internalization rate constant (Ke or Ke obs) or 
as a % of Ke in control cells, as indicated, and are the mean of duplicate or triplicate points. 
Statistical analysis was performed using JMP 10.0 statistical software (SAS Institute, Inc). 
Student's t-test was used to calculate statistical significance among at least two biological 
replicas of the different conditions.  
 
9.2   Saturation binding with 
125
I-EGF  
Cells were serum starved for at least 2 hours and then incubated in the presence of 5 ng/ml of 
125
I-EGF in binding buffer (MEM, BSA 0.1%, Hepes pH 7.4 20 mM). To reach the final 
concentration of 100 ng/ml, unlabelled EGF was added to the mix. The cell were cooled on 
ice for 30 minutes and incubated at 4°C with mix containing 
125
I-EGF. After six hours, cells 
were washed three times in PBS, and then were lysed with 300 l of a solution containing 1M 
NaOH. This sample represents the amount of 
125
I-EGF bound at the equilibrium, which is 
dependent on the number of EGFRs on the cell surface. The unspecific binding was measured 
at each time points in the presence of an excess of non-radioactive EGF (300X). After being 
corrected for non-specific binding, the assay provides the quantitative measurement of the 
number of EGFRs for each well. By counting the number of cells plated in each well, this 
assay allows to measure the number of surface EGFRs/cell.  
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9.3   EGFR recycling assay with 
125
I-EGF 
Cells were plated into 24 wells. The day after, cells were serum-starved for at least 2 hours in 
binding buffer and incubated for 15 minutes at 37°C with 20 ng/ml of 
125
I-EGF: 5 ng/ml of 
125
I-EGF  + 15 ng/ml of cold EGF. Then, cells were put on ice, washed twice with cold PBS 
and incubated with mild acid/salt wash buffer (0.3 M Na acetate, 0.5 M NaCl pH 4.5) for 5 
min and then washed 2 times with cold binding buffer. These cells (further referred to as 
“125I-EGF-loaded cells”) contained a large pool of intracellular 125I-EGF and a minimal (less 
than 5%) surface pool of 
125
I-EGF. 
The 
125
I-EGF-loaded cells were further incubated in binding medium with 4 ug/ml of 
unlabeled EGF at 37 °C for a chase time
 (0’, 20’, 40’, 60’, 90’), and the amount of degraded 
and intact 
125
I-EGF in the medium as well as surface and intracellular labeled ligand was 
determined. Briefly, after each time points: i) the medium is collected, half to count directly 
(free total), half to perform TCA precipitation to distinguish between intact/recycled EGF 
(pellet) and degraded EGF (supernatant). The amount of degraded or intact ligand 
radioactivity in the medium/lysate was determined by precipitating with 5% trichloroacetic 
acid and counting supernatant and pellet. ii) Cells were washed twice with cold PBS and 
incubated with acid wash buffer pH 2.5 for 5 min at 4°, to determine the amount of surface-
bound 
125
I-EGF. iii) Cells were lysed in 1 N NaOH to determine the internalized amount of 
125
I-EGF. 
 
9.4   EGFR degradation assay with 
125
I-EGF 
Cells were plated into 24 well. The day after, cells were serum-starved for at least 2 hours in 
binding buffer and incubated for 15 minutes at 37°C with 20 ng/ml of 
125
I-EGF: 5 ng/ml of 
125
I-EGF  + 15 ng/ml of cold EGF. Then, cells were put on ice, washed twice with cold PBS 
and incubated with mild acid/salt wash buffer (0.3 M Na acetate, 0.5 M NaCl pH 4.5) for 5 
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min and then washed 2 times with cold binding buffer. These cells (further referred to as 
“125I-EGF-loaded cells”) contained a large pool of intracellular 125I-EGF and a minimal (less 
than 5%) surface pool of 
125
I-EGF. 
The 
125
I-EGF-loaded cells were further incubated in binding medium with 4 ug/ml of 
unlabeled EGF at 37 °C for a chase time
 (0’, 20’, 40’, 60’, 90’), and the amount of degraded 
and intact 
125
I-EGF in the medium as well as surface and intracellular labeled ligand was 
determined. Briefly, after each time points: i) the medium is collected, half to count directly 
(free total), half to perform TCA precipitation to distinguish between intact/recycled EGF 
(pellet) and degraded EGF (supernatant). The amount of degraded or intact ligand 
radioactivity in the medium/lysate was determined by precipitating with 5% trichloroacetic 
acid and counting supernatant and pellet. ii) Cells were washed twice with cold PBS and 
incubated with acid wash buffer pH 2.5 for 5 min at 4°, to determine the amount of surface-
bound 
125
I-EGF. iii) Cells were lysed in 1 N NaOH, half of the lysate was used to count 
directly (internalized total), half to perform TCA precipitation to distinguish between intact 
EGF (pellet) and degraded EGF (supernatant). 
 
10. EGFR degradation  
800,000 cells were plated on five 10-cm dishes. The day after cells were serum starved for 16 
hours and stimulated for the indicated time points with high dose EGF. For EGFR 
degradation 15 µg of total cell lysate were loaded on a 7% SDS polyacrylammide gel. 
Western blots were performed as described in section 7.3. 
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11. Immunofluorescence and colocalization studies 
11.1   IF-based EGF internalization assays and colocalization analysis 
HeLa cells, plated on glass coverslips, were incubated at 37°C for the indicated times with 
high dose Alexa-conjugated EGF. Samples were then fixed in 4% paraformaldehyde. When 
indicated, acid wash treatment was performed before fixation, by incubating cells for 10 min 
at 4°C in an acidic buffer (acetic acid 0.2 M, NaCl 0.5 M) pH 2.5 followed by washes with 
Hepes-supplemented medium to restore pH before fixation. Cells were then permeabilized 
with 0.1% TritonX-100 in PBS supplemented with 1% (w/v) BSA, and labeled with primary 
antibodies against the protein of interest in PBS/BSA, followed by visualization by incubation 
with specific secondary antibodies. Images were obtained using a Leica TCS SP2 or TCS SP2 
AOBS confocal microscope equipped with a 63X oil objective and processed using ImageJ.  
 
11.2   In vivo internalization assays of EGFR or CD147 using antibodies 
For antibody internalization assays, serum-starved HeLa cells were incubated with anti-EGFR 
13A9 or CD147 antibody for 30 min at 4 °C or for 5 min at 37 °C (to avoid temperature shift), 
with comparable results. Cells were then stimulated with high dose Alexa-conjugated EGF at 
37 °C for the indicated times. After internalization, cells were fixed and processed for IF. For 
CD147 internalization assays (45), non-permeabilized cells were incubated with an excess of 
Alexa-647 secondary antibody in PBS/BSA 1% (to saturate PM-localized CD147 antibody), 
followed by permeabilization and incubation with an Alexa-488 secondary antibody to label 
the internalized CD147 antibody (note that also residual PM-localized CD147, not-saturated 
by the Alexa-647 secondary antibody, is stained).  
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12.   Super-Resolution Microscopy  
HeLa cells were labeled in vivo for EGFR, stimulated with 100 ng/ml EGF for 2 min at 37°C, 
or left unstimulated. Additionally, HeLa cells stimulated with 1 ng/ml EGF for 2 min at 37°C 
were used to analyze cross-correlation in conditions where only CME is active. Samples were 
fixed in 4% paraformaldehyde, permeabilized and then labeled with anti- antibody, followed 
by incubation with anti-mouse Cage-550 and anti-rabbit Alexa 647 secondary antibodies. 
 Super-resolution localization imaging was obtained by direct stochastic optical 
reconstruction microscopy (dStorm) (138). Briefly, the fluorescent molecules are induced to 
blink on and off by reducing agents included in the imaging medium. If few molecules are 
fluorescent at each time, so that the diffraction limited spots corresponding to individual 
fluorophores are well separated, the position of each molecule can be quantified with higher 
accuracy than the resolution limit (196). By acquiring multiple images of the same field (tens 
to hundreds of thousands), and storing the position of the localized molecules at each frame it 
is therefore possible to obtain an image of the sample with resolution higher than the 
diffraction limit. 
 dStorm was performed on a Leica SR GSD-3D (Leica Microsystems Srl, Milan, Italy) 
super-resolution microscope equipped with a 150x 1.45NA objective, an Andor iXon Ultra-
897 EM-CCD sensor and three solid state lasers (405 nm 100 mW, 488 nm 300 mW, and 647 
nm 500 mW). The sample was mounted on the stage and the medium was substituted prior to 
acquisition with a mix of glucose oxidase (560 µg/ml), catalase (400 µg/ml) and cysteamine 
HCl (100 mM) in TN buffer with 10% glucose (w/v) pH 8.0, to induce blinking of the 
fluorophores (197). Alexa 647 and Cage 500 were imaged sequentially (starting from the red 
channels). 30,000 images were collected for each channel with 5 to 20 ms exposure times and 
an increasing ramp of 405 nm laser intensity with powers between 0 and 0.8 mW was used to 
reactivate the molecules in long-lived dark states. Only localization events occurring at the 
periphery of the cell were considered (within 2 µm from the PM). Furthermore, localization 
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events with less than 20 photons/pixel for the Alexa 647 dye and 40 photons/pixels for the 
Cage 500 dye were discarded. The list of the detected molecules in the two channels was used 
to compute the cross-correlation of the two images as described in (139): the cross-correlation 
curve was then fit by an exponential decay to quantify the degree of colocalization between 
EGFR-Cage500 and RTN3-Alexa647 and the size of the co-clusters, respectively provided by 
the cross-correlation amplitude C0 and the correlation length Rc. For visualization purposes, 
the super-resolution images were reconstructed by rendering each of the detected molecules 
as a Gaussian distribution, with width equal to the localization precision of each event. 
 
13.   FRET  
Cells were acquired with a Zeiss LSM 510 confocal microscope through a Plan-Apochromat 
sec. ECFP and EYFP were excited through an Argon laser at 458 and 514 nm respectively, 
while EGF-555 was excited with a HeNe laser at 546 nm. Emissions were selected with the 
following band pass filters: BP 470-500 for ECFP, BP 530-600 for FRET and EYFP, BP 560-
615 for EGF-555. 
Sensitized emission FRET (SE-FRET) were calculated by a custom macro written for the 
open source FIJI software according to (198). For sensitized emission calculations, single 
fluorescent protein images for each channel were acquired.  
In Figure 16B, SE-FRET from the whole cell was collected. Statistical analysis was by 
Student’s t test. In Figure 16C, SE-FRET extent was collected only in the plasma membrane 
regions exposed to EGF-555 by obtaining a binary mask on the EGF-555 images. Binarized 
EGF-555 masks were filtered by structures smaller then 0.2 µM
2
 to exclude endosomal EGF-
555. 
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14.   Immunoelectron Microscopy 
14.1   Sample preparation 
For ER labeling, cells were transfected with HRP-KDEL (142); 24 hours after transfection, 
cells were subjected to pre-embedding immunolabeling with anti-EGFR 13A9 antibody 
followed by incubation with rabbit anti-mouse, and, finally, with Protein-A Gold 10 nm (30 
min incubation on ice/each step). Cells were then incubated at 37°C for 2, 5 or 8 min with 30 
ng/ml EGF, as indicated. A control sample left at 37°C for 5 or 8 min without EGF was 
included in the experiment to control that no internalization was induced by the antibody in 
the absence of ligand. Cells were then washed in PBS and fixed for 1 h at room temperature 
in 1.2% glutaraldehyde in 66 mM sodium cacodylate buffer pH 7.2 containing 0.5 mg/ml of 
ruthenium red. After quick washes with 150 mM sodium cacodylate buffer, the samples were 
post-fixed in 1.3% osmium tetroxide in a 66 mM sodium cacodylate buffer (pH 7.2) 
containing 0.5-mg/ml ruthenium red for 2h at room temperature. Cells were then rinsed with 
150 mM NaCacodylate, washed with distilled water and enbloc stained with 0.5% uranyl 
acetate in dH20 overnight at 4°C in the dark. Finally, samples were rinsed in dH2O, 
dehydrated with increasing concentrations of ethanol, embedded in Epon and cured in an oven 
at 60°C for 48 h. 
 
14.2   Image acquisition and analysis 
To quantify the percentage of EGFR endocytic invaginations associated with ER tubules, the 
PM of HRP-stained cells was scanned and when an EGFR-positive endocytic structure 
(clearly connected to the PM) was encountered (CCP or TI), EM micrographs of this region 
and of the same area on the previous and next serial sections were acquired. The three serial 
sections images were aligned in IMOD (3dmod Ver 4.7.9) and imported in ImageJ, where 
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selection lines at ≤ 20 nm from the membrane of the endocytic structure were overlaid on the 
three images. An endocytic structure was considered associated with an ER tubule if at least 
in one section an ER tubule was present inside the delimited area. 
 
15.   Measurements of intracellular Ca
2+
 concentration.  
15.1   Aequorin measurements. 
Cells grown on 13-mm-round glass coverslips at 50% confluence were transfected with the 
appropriate cytosolic (cyto)- or PM-targeted aequorin chimeras. Aequorin constructs and 
protocols were previously described (195). All aequorin measurements were performed in 
KRB buffer (135 mM NaCl, 5 mM KCl, 0.4 mM KH2PO4, 1 mM MgSO4, 20 mM HEPES 
and 5.5 mM glucose, pH 7.4), supplemented with 1 mM Ca
2+
. When EGTA treatment was 
performed, aequorin measurements were recorded in KRB buffer plus 100 µM EGTA. 
Stimulation with EGF was performed as specified in the figure legends. The experiments 
were terminated by lysing the cells with 0.01% Triton in a hypotonic Ca
2+
-rich solution (10 
mM CaCl2 in H2O), thus discharging the remaining aequorin pool. The light signal was 
collected and calibrated into [Ca
2+
] values, as previously described (195). Extents of Ca
2+
 
waves were expressed as area under the curve (AUC) and maximal value of peak in box plot 
graphs. Statistical analysis was performed using GraphPad Prism. Student’s t-test was used to 
calculate statistical significance among different samples. 
 
15.2   Fura-2, AM, measurements 
Cells were grown on 24-mm coverslips and incubated at 37°C for 30 min in 1 mM Ca
2+
/KRB 
supplemented with 2.5 mM Fura-2 AM, 0.02% Pluronic F-68, and 0.1 mM sulfinpyrazone. 
The cells were then washed and supplemented with 1 mM Ca
2+
/KRB. Prior the acquisition 
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cells were washed and supplemented with 1 mM Ca
2+
/KRB. To determine the cytosolic Ca
2+
 
response, cells were placed in an open Leyden chamber on a 37°C thermostat-controlled stage 
and exposed to 340/380 nm wavelength light using the Olympus xcellence multiple-
wavelength high-resolution fluorescence microscopy system equipped with an ORCA ER 
CCD camera (Hamamatsu Photonics) and an Uplan FLN 40X oil objective (Olympus). After 
registration of baseline ratio, cells were stimulated with Alexa555-EGF. Fluorescence data 
collected were expressed as emission ratios. The extent of Ca
2+
 waves was expressed as AUC 
in box plot graphs. Statistical analysis was performed using GraphPad Prism. One-way 
ANOVA was used to calculate statistical significance between different samples. 
 
15.3   GCaMP6f measurements 
Cells were grown on 24-mm coverslips, and transfected with the construct 48hr prior the 
acquisition of images. For the acquisition, cells were washed and supplemented with 1 mM 
Ca
2+
/KRB. To determine the cytosolic Ca
2+
 response, cells were placed in an open Leyden 
chamber on a 37°C thermostat-controlled stage and exposed to 490/406 nm wavelength light 
using the Olympus xcellence multiple-wavelength high-resolution fluorescence microscopy 
system equipped with an ORCA ER CCD camera (Hamamatsu Photonics) and an Uplan FLN 
40X oil objective (Olympus). After registration of baseline ratio, cells were stimulated with 
Alexa555-EGF. Fluorescence data collected were expressed as emission ratios. The extent of 
Ca
2+
 peaks was expressed as AUC in box plot graphs. Statistical analysis was performed 
using GraphPad Prism. One-way ANOVA was used to calculate statistical significance 
between different samples. 
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15.4   Xestospongin C treatment 
Cells were treated with 2 µM xestospongin C for 16 h. The drug was kept for the duration of 
the different experimental procedures (Fura-2 AM measurements or CD147 internalization). 
 
15.5   Calcium depletion with ionomycin 
Calcium depletion was obtained by administration of 100 µM EGTA in a calcium free KRB 
supplemented with 1 µM ionomycin at 4°C to reduce SERCA activity. Forty-five minutes of 
depletion procedure was sufficient to induce complete depletion of Ca
2+
, as previously 
described (146). 
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